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ABSTRACT
EVALUATION OF THE SAFETY AND PHARMACOKINETIC PROFILE OF THE
BROAD SPECTRUM ANTIVIRAL LECTIN GRIFFITHSIN
Christopher Lynn Barton
June 23, 2014

Carbohydrate binding agents that target viral envelope glycans are being
studied for their potential use as microbicides and antiviral therapeutics.
Griffithsin is a lectin originally identified in a red alga Griffithisia sp. Multiple
studies have shown that GRFT inhibits HIV-1, Coronaviruses, Hepatitis C,
influenza and Ebola virus replication in vitro. This antiviral activity suggests
potential uses in chemoprophylaxis and disease treatment. However, safety of
GRFT administration has not been extensively studied. In vivo testing--chronic
subcutaneous treatment as well as single dose subcutaneous, oral, and
intravenous administrations of Griffithsin in Sprague Dawley Rats (Rattus
Norvegicus)--was used to assess Griffithsin’s pharmacokinetic properties and to
predict whether use of Griffithsin for antiviral treatment might be safe and
effective. Based on histological, serological, and biochemical data derived from
these experiments, Griffithsin is generally well tolerated. However, protein
v

binding assays revealed interactions with complement and apolipoproteins and
calorimetric assays revealed changes in serum thermograms that may require
further study.
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CHAPTER 1
INTRODUCTION AND BACKGROUND

A number of enveloped viruses continue present significant threats to
public health in the United States and the developing world. Discovery and
development of antivirals with broad spectrum activity is important for both
antiviral prophylaxis as well as for therapy.
Perhaps the most significant viral epidemic in the recent past is Human
Immunodeficiency Virus (HIV). With no effective vaccine, HIV-1, affects over 35
million people worldwide, and still claims the lives of millions of people per year
despite effective treatment options [1]. In the United States alone, approximately
50,000 new infections still occur yearly, with over 50% of those infections being
among men who have sex with men (MSM). Other enveloped viruses also cause
persistent viral infections and present serious threats to public health. Aside from
HIV-1, the most clinically significant persistent viral infections are caused by
Hepatitis C Virus (HCV), and human herpesviruses such as cytomegalovirus
(CMV), Karposi’s sarcoma-associated herpesvirus (KSHV), and type 2 herpes
simplex virus (HSV-2). Viruses that cause chronic, often life-long infections have
1

all needed to evolve strategies to evade the host immune response. Viruses use
a diverse range of immune evasion strategies, from blocking the interferon
response through induction of interfering ribonucleic acids (RNAs) [2-7]. For
example, HIV-1 employs many of these strategies ranging from inhibition of
humoral immune responses by complement to antigenic variation attributable to
low fidelity reverse transcriptase [8, 9]. Further, HIV-1 downregulates interferon
(IFN) production to prevent an immune response [10], as well as possibly
encodes silencing RNAs [11, 12]. Many of the viruses that persist for long
periods of time display dense glycan shields on their envelopes to evade humoral
immune responses by display of “self” epitopes that occlude functionally
important domains of the envelope proteins, and in some cases to suppress
induction of an immune response.
Enveloped viruses from taxonomic families not necessarily linked by a
common evolutionary history often display heavily glycosylated envelope
glycoproteins. Dense, asparagine-linked (N-linked) glycans attached to viral
surface proteins are a common structure amongst these viruses [13, 14]. These
glycans present on viral envelope proteins have roles in host immune evasion
and modulation, as well as stabilization of viral envelope structures [15-17]. In
the case of HIV, oligomannose glycans have been theorized to assist in immune
evasion through presentation “self” epitopes [18], as well as down-regulation of
INF production and immunosuppressive cytokine induction under some
circumstances [2, 10, 19, 20].
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While glycans are structurally important for these viruses, they also
present new targets for antiviral agents. Agents which could selectively bind
these glycans could thus be attractive targets for ongoing antiviral research –
both as a preventative as well as a treatment [21]. In recent years, natural
product derived lectins have been recognized for this very purpose [14, 22-24].
These lectins have been observed to inhibit viral transmission by binding to the
specific N-linked glycans present on the surface of the viral envelopes [14]. In so
doing they have the effect of preventing viral fusion and entry [22, 25-27].
Outcomes of lectin therapy have also generally been positive. Animal
survival and amelioration of viral infection has been observed in a number of viral
challenges. Treatment with cyanovirin (CV-N) conveyed marked survival
benefits in a murine influenza challenge [28]. Treatment with large
concentrations of human mannose binding lectin (MBL) conveyed a survival
benefit versus Ebola virus challenge in mice [29]. Additionally, HCV infection has
been modestly inhibited through lectin therapy [30, 31].
Griffithsin (GRFT) is a lectin originally identified from the red algae
Griffithisae sp [32]. Now recombinantly produced in tobacco plants, GRFT is a
candidate topical microbicide and systemic therapeutic [33, 34]. In vitro studies
into GRFT’s anti-HIV-1 activity have demonstrated an average inhibitory EC50 of
40 pM [32]. While initially investigated as a microbicide, systemic administration
studies are currently underway to evaluate potential uses of GRFT in antiviral
therapy [34].

3

Given GRFT’s potent antiviral activity and low immunogenicity, GRFT has
the diverse potential applications, including use as a systemic anti-viral therapy,
chemoprophylaxis, or microbicidal agent [35-37]. The purpose of this
dissertation is to explore GRFT’s potential usage as a pre-exposure prophylaxis
and systemic therapeutic for enveloped viruses possessing high-mannose Nlinked glycans. While GRFT has activity against multiple viruses, this
dissertation focuses on GRFT in the context of HIV-1 infection given robust in
vitro assays to measure and analyze GRFT’s anti-HIV activity in serum and other
biological products. The specific aims of these studies included: evaluation of
GRFT’s practical pharmacokinetic parameters to elucidate how method of
administration may impact GRFT’s utility; evaluation of GRFT’s potential as an
orally dosed rectal microbicide through gastric lavage of different concentrations
of GRFT in rats; evaluation of GRFT’s systemic impacts both in the presence and
absence of an antibody response with accompanying intermediate-term dosing;
and identification of GRFT’s potential endogenous serum protein binding
partners through affinity purification; as well as evaluation as to whether
Differential Scanning Calorimetry is capable of revealing alterations in serum
protein interactions following both chronic systemic administration and serum
spiking of GRFT.
Glycosylation States
Glycosylation is enzymatic addition of complex carbohydrate chains to
organic molecules, such as proteins [38]. These additions assist in maintaining
proper protein folding, increase protein stability, and contribute to protein
4

functionality [39]. Furthermore, glycosylation can result in greater hydrophilicity.
Viral glycosylation can also alter infectivity and viral fitness [40].
Glycosylation is a covalent post-translational modification that can occur in
either the Golgi apparatus or the endoplasmic reticulum and is fundamental to
many biological processes [29]. This modification process can result in five
different types of glycans (glycoforms) can result: N-linked, O-linked, C-linked,
glipiated, or phospho-glycans [29]. The glycoform relevant to the studies at hand
are of the N-linked variety, given GRFT’s high affinity for oligomannose N-linked
glycans.
N-linked glycosylation begins with the addition of a 14 unit oligosaccharide
precursor to an asparagine in a polypeptide chain. The signal for N-linked
glycosylation occurs through one of two sequences: Asn-X-Ser or Asn-X-Thr,
where X can be any amino acid except proline [41]. The general branched
carbohydrate chain contains 3 glucose, 9 mannose, and 2 N-acetylglucosamine
molecules attached to a carrier molecule (a dolichol), and transferred to the
appropriate signal sequence on the protein as it is translocated into the ER
lumen [42].
Saccharide compositions between glycans of the same linkage type may
also vary, leading to High-mannose, Hybrid, or Complex glycans (with the
terminal structure presented after editing determining the glycan subtype) (Figure
1.1) [29]. High-mannose glycans exclusively present mannose on the terminal
portions of the sugar, and contain 5-9 mannose residues [29] (Figure 1.1 A &B).
No N-acetyl glucosamine residues are presented. As the initial state for many
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glycans, further editing occurs which result in either Complex (Figure 1.1 D) or
Hybrid glycans (Figure 1.1C) [29]. This editing is thought to depend on
accessibility to multiple saccharide-modifying proteins present in the Golgi [29].
Further editing results in either Hybrid glycans – where at least one mannose
residue and one N-acetylglucosamine are presented, or Complex glycans [29].
Complex glycans, which do not have mannose terminal residues, can have
multiple N-acetyl glucosamines or other terminal sugar structures presented [29].
Endogenous glycans have many vital physiological roles. Glycans can
prevent self-recognition and autoimmunity[43]. Functionally, glycans can
stabilize protein folds as well as become vital parts of extracellular matrix [44].
Further, glycans can function in cell trafficking and communication through
recognition of glycan binding proteins[45]. In the case of antibodies and other
circulating proteins, serum half-life and cell receptor interaction may be
influenced by glycosylation [46-49].

Viral Glycosylation
Upon taking over the cellular machinery upon infection, virally produced proteins
are also known to be glycosylated. In the case of HCV, a number of envelope
proteins are glycosylated [17, 50]. Further, as mentioned previously, these viral
glycans assist in immune evasion, with the loss of the glycans related with
increased susceptibility to antibody neutralization [17, 51, 52]. Influenza virus
also present glycosylated glycans [40]. Influenza hemagglutinin (HA) initiates the
infection process by binding to cellular receptors and is known to possess
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multiple glycosylation sites which has been linked to virulence in mice[53]. The
Severe Acute Respiratory System Coronavirus(SARS-CoV) possesses a number
of glycosylation sites, particularly in the S glycoprotein necessary for cellular
binding[54, 55]. Ebola virus possesses both N- and O-linked glycans[56, 57].

HIV-1 – A virus possessing Oligomannose N-linked glycans
HIV-1, a lentivirus of the retrovirus family, continues to spread worldwide [58].
HIV’s genome consists of nine genes[59]. Six genes in the HIV genome: tat,
rev, nef, vif, vpr and vpu code for viron processing [59] Whereas, Gag, Pol, and
Env encode structural and functional proteins [59]. Many of the proteins
produced are precursors that require additional modification. Gag encodes
protein which is cleaved into matrix (p17), capsid (p24), nucleocapsid (p7), and
p6 [59]. Similarly replication proteins associated with cDNA synthesis and cDNA
integration are generated as precursors cleaved to produce viral protease,
reverse transcriptase and integrase [59].
Virion surface glycoproteins gp120 and gp41 are encoded on the Env
gene. These glycoproteins are initially synthesized as a 160kDa glycoprotein
precursor protein, requiring cleavage before assembly into a spike [59].
Following glycosylation in the endomembrane system, gp160 is enzymatically
cleaved into gp120 and gp41 [43]. Trimerization of three molecules of gp41 with
gp120 molecules spikes on the viral envelope for interacting with CD4 receptor
molecules [59].
GP120 structure and glycosylation
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Gp120 protein of HIV is highly glycosylated, with an average of 24
glycosylation sites occupied [55]. Further, those glycans are almost entirely of
the high-mannose variety [13, 60]. These glycans can greatly impact viral
infectivity and fitness. For example, an increase in potential N-linked
glycosylation sites can result in increased viral fitness by obscuring binding sites
recognized by antibodies [56]. Additionally, viruses isolated from early time points
in infection tend to be less heavily glycosylated than viruses isolated from later
time points [57, 58].

HIV Infection
Cellular binding is the first step in the process of HIV infection. Viral
particles with reduced numbers of N-linked glycans infect activated T-cells and
dendritic cells in the genital mucosa [61-64]. CD4+ T cell infection results in
migration of the virus to gut-associate lymphoid tissues [65, 66]. There acute
infection takes hold as gut-associated T-cells possessing the α4β7 gut homing
integrin are infected and depleted [64].
The routes of sexual exposure and transmission may vary. Vaginal
transmission is the most common route of transmission worldwide, though in the
United States the majority of new infections occur via rectal exposure[67]. In
vaginal transmission, the cervix is a major site for HIV-1 transmission as rich in
HIV-1 target cells [68-70]. However, receptive anal intercourse provides the
greatest probability of transmission [71, 72]. Fragile rectal tissue which can be
damaged by intercourse, and a large population of T cells and dendritic cells
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resident in the rectal mucosa contribute to high probability of productive infection
[71, 73-77].
The biochemical steps of cellular infection begin with gp120 present on
the envelope of HIV binding with the CD4 receptor molecule expressed on the
surface of mature CD4+ T cells, macrophages and dendritic cells [78-80]. Upon
binding, the CD4 receptor molecule undergoes conformational changes with
allow for interaction with either of two 7-transmembrane spanning chemokine
receptors, CCR5 or CXCR4 [81-83]. Co-receptor engagement and binding leads
to a second conformational change in the viral envelope spike, altering the state
of gp41 [84, 85]. This alteration of gp41 leads to insertion of the N-terminal
domain of gp41 into the cellular membrane. This insertion triggers formation of a
six-helix bundle that provides the energy for cellular fusion. [84-86]. Upon fusion,
the viral capsid releases two copies of RNA, reverse transcriptase, integrase,
and viral protease. Reverse transcriptase acts to convert the RNA into DNA
while Integrase cleaves host DNA and integrates the new viral DNA into the host
cell genome. Later, viral protease acts to cleave precursor polyproteins into
functional proteins for new virion packing and assembly.
Within weeks of infection, some persons display Acute Retroviral
Syndrome associated with primary HIV infection. During that period, a large
burst of viral replication occurs as the immune system reacts to the infection,
attempting to eliminate the virus and infected cells. During this period,
nonspecific symptoms such as fever, rash, body aches occur as a consequence
of immune system activation. After a number of days to weeks, symptoms
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resolve, however the immune system is remains in a persistent inflammatory
state. Despite a lack of outward symptoms, a slow but steady decrease in CD4+
cells occurs over a number of years. During this time, a gradual increase in viral
load accompanies the decrease in CD4+ t cells.

Prevention Methods and Antiviral treatments
Pharmacological strategies are currently in use for the treatment of many
of enveloped viruses, with small molecule pharmaceuticals designed to block
specific events in the viral life cycle. These strategies include
preventing/reducing viral replication, preventing virion processing and maturation,
as well as preventing viral entry into cells.
HIV-1 currently has many treatment options available for infected
individuals with the goal of suppressing viral replication below the limits of
detection. However, maintenance of an undetectable viral load may be difficult to
maintain due to drug side effects, drug adherence, and emergence of drug
resistant virions. As such, a long acting adjuvant treatment acting upon a novel
drug target may be useful for those with adherence issues, or those with few
treatment options left. As such, anti-viral lectins targeting N-linked oligomannose
glycans present on HIV-1 gp120 spike proteins may be a new treatment option
for maintaining an undetectable viral load, and thus maintaining the health
benefits an undetectable viral load brings.
Drugs to suppress HIV infection currently include non-nucleoside reverse
transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease
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inhibitors, integrase inhibitors, and fusion/entry inhibitors. Collectively known as
Highly Active Anti-Retroviral Therapy (HAART), these medications, when given in
combination therapy, offer the potential for infected individuals to live a normal
lifespan [87]. The goal of HAART is to as suppress viral load to undetectable
levels. In many cases, this leads to preservation of immune function [88].
Further, due to continued thymic output, durable viral suppression is often
accompanied by a restoration of CD4+ cell populations [89, 90]. However, even
in those who are virally suppressed, as significant subset, known as
immunological non-responders, fail to see full immune system recovery [88, 91].
Prior to the initiation of HAART, genetic testing is conducted to determine
HIV-1 drug resistances. With this knowledge in hand, the typical regimen
consisting of 3 or more drugs of at least two classes is chosen [92, 93]. After
initiation of HAART, the majority of patients see a very rapid decline in viral load
levels as well as an increase in CD4+ T cells [94, 95]. Many individuals can
achieve undetectable viral loads with vigilant adherence to therapy [94]. Further,
increases in CD4 cells counts can continue for years after durable viral
suppression is achieved [88, 95-97]. Nonetheless, lifetime adherence to therapy
is currently required.
One complicating factor in disease management is that once HIV-1 is
systemically established, viral reservoirs appear to make systemic eradication of
the virus impossible [98-101]. Viral reservoirs are believed to be the latent
infection of long lived memory cells. However, it is also possible that a low level
viremia intermittently continues or a combination of both of those factors [98-
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102]. The practical effect of this latent infection is seen through the fact that
shortly after discontinuing HAART, viral load levels rebound in the majority of
patients.
In addition to viral rebound after discontinuation of therapy, intervening
periods of low level viral replication can occur. Despite durable suppression of
viral replication, T-cell activation during times of illness or infection can cause
bursts of HIV-1 replication activity in infected cells[94]. The clinical significance
of these “blips” are currently not thought to be relevant[103]. However, it is
possible that detectable viremia may be indicative of the acquisition of viral
resistance[103].
Nonetheless, many studies now support the notion that undetectable viral
loads are the primary goal of treatment. Studies have indicated that
undetectable viral load levels could be even more important than CD4+ counts
[104]. Thus a patient who is consistently undetectable in their viral load testing
may need less periodic testing for CD4 counts [104]. As such, anti-viral agents,
such as antiviral lectins, that could further prevent cell-to-cell transmission of HIV
during periods intermittent or transient viremia may aid in maintaining
undetectable viral loads.

Pre-Exposure Prophylaxis (PrEP)
Recently, a new prevention method was approved for usage within the
United States which validates the concept of patient pre-treatment with anti-viral
agents to prevent HIV-1 infection. Pre-exposure Prophylaxis (PrEP) is a
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chemotherapeutic intervention that offers the promise of preventing HIV-1
infection if used as directed [105, 106]. PrEP currently consists of administration
of antiviral drugs to HIV negative persons at risk for infection [107]. Presently,
Truvada (a combination of emtricitabine and tenofovir) is the only drug
combination provided to high-risk, HIV-1 negative, individuals [96]. If taken daily
as directed, PrEP has been observed to substantially reduce chances of HIV-1
infection after exposure [105, 108]. Nonetheless, PrEP is not devoid of risks.
Rarely, kidney damage and malfunction can occur which would necessitate
cessation of PrEP [109-112]. As such, frequent kidney function testing is
recommended [96]. As such, this emerging field prevention method is likely to
increase as additional antiviral drug interventions are validated.

Treatment as Prevention (TasP)
A second concept which underscores the need to maintain undetectable
viral loads is summarized as Treatment as Prevention (TasP) [113]. Preliminary
results from the PARTNER study have shown no transmissions between
individuals when the positive partner has an undetectable viral load [114]. While
the final results of the study will not be available for a number of years, it appears
that an undetectable viral load in a positive individual strongly correlates with
infectiousness [115, 116]. As such, attaining and maintaining an undetectable
viral load may prove crucial in curbing new infections.
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Post Exposure Prophylaxis (PEP)
Post Exposure Prophylaxis (PEP) has also been used successfully to
prevent viral infection [117-120]. PEP consists of a month long course of antiretroviral medication after both occupational and nonoccupational exposures.
With needlesticks being a common occupational exposure, PEP has been
observed to be effective in preventing infection [120]. Further, in a nonoccupational exposure setting, such as condom breaks during intercourse, PEP
has shown great efficacy [119]. However, it typically must be initiated within 48
hours after exposure in order to reduce the odds of transmission.

Entry Inhibitors
Entry inhibitors that prevent viral fusion with its target cell at various
phases of the viral entry process are currently being used in treatment and
research. These agents target proteins on either the HIV-1 virus or the cell.
Targets include: gp120 of HIV-1, gp41 of HIV-1, and T-cell receptors and coreceptors. Entry inhibitors mechanistically present a barrier to infection through
binding activity to viral or cellular receptors necessary for infection [33, 121].
Entry inhibitors that neutralize the virus, such as isolated broadly
neutralizing monoclonal antibodies, are potential chemoprophylactic and
therapeutics for HIV-1. These broadly neutralizing antibodies recognize epitopes
(such as gp41, V1V2-glycans, and the CD4 binding site) on the HIV-1 envelope
and can neutralize multiple strains. For instance, antibody b12 recognized the
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CD4 binding site of HIV-1 [122], whereas 2G12 recognizes the outer domain
glycan [123]. Other monoclonal antibodies, such as 3BNC117 and 10-1074,
which target the CD4 binding site and V3 region respectively, have been
examined both as monotherapy and together in a Macaque SHIV models [124].
When used individually, emergence of neutralization-resistant variants often
limits their long term utility [124]. However, broadly neutralizing may hold promise
when used in cocktails to treat chronic HIV infection [124, 125].
While many entry inhibitors directly act on the virus, an alternative
approach may include the competitive blockage of receptor or co-receptor
molecules on HIV target cells. For example, Ibalizumab is a nonimmunosuppressive CD4-targeting IgG molecule [126-128]. Ibalizumab binds the
CD4 molecule present on T-cells receptors in the D2 region [129, 130]. While
blocking portions of the CD4 receptor, it does not interfere with binding of MHC II
molecules or the gp120-- thus it does not interfere with normal immune function
[129-131].
Enfuvirtide, is a 36 amino acid peptide mimic of the HR2 fragment of gp41.
Functionally it binds to the HR1 region of gp41 [132, 133]. Enfuvirtide binding
blocks formation of the six helix bundle required for the cellular fusion process
[85]. While it is an injectible peptide fusion inhibitor [134], it was approved for
treatment of HIV infection in 2003 [135].
Maraviroc is CCR5 co-receptor antagonist [136-138]. Maraviroc binds to
the transmembrane cavity of the CCR5 co-receptor, halting the co-receptor
interactions necessary for viral fusion [139].
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Entry Inhibitors – Antiviral Lectins
Lectins are also being investigated as potential HIV-1 entry inhibitors [22].
Lectins are highly specific carbohydrate binding proteins. In animals, lectins can
function in the immune system recognition of carbohydrates exclusively
presented by pathogens. For example, mannose binding lectin is protein of the
innate system that activates complement or triggers pathogen opsonization [83].
Antiviral lectins consist of a subset of lectins which bind to viral envelope
glycans [22]. Among these are Griffithsin (GRFT), Scytovirin (SVN), Bananna
lectin (BanLec), Concanavalin A (ConA), Cyanovirin-N (CVN), and Actinohivin
[27, 140-142]. While different lectins have different carbohydrate targets, such
as high-mannose glycans or complex glycans, lectins specific for HIV glycans are
thought to bind high-mannose glycans of gp120, preventing cell fusion [21, 22,
143].
Despite their promise, lectin therapy may be challenging. First,
exogenous lectins, like Phytohemagluttinin (PHA), are well known to agglutinate
red blood cells [144] and often induce mitogenic and cytotoxic effects [145].
Second, lectins are often considered anti-nutrients given their sugar binding
activities [146]. For example, large consumption of lectins can cause side effects
such as diarrhea, nausea, and vomiting [147]. Finally, lectins may interact with
leptin receptors, leading to leptin resistance [148].
In vitro studies with antiviral lectins have also identified a number of
potential issues. For instance, studies into CVN, which binds to alpha (1,2)
mannose termini, have identified cell morphology changes in PBMC’s treated
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with CVN as well as increased expression of cellular activation markers [149].
These changes rendered the PBMCs more susceptible to HIV-1 infection by R5
trophic variants. Further, CVN was found to increase production in a number of
cytokines. BanLec, a potent anti-HIV-1 lectin with specificity for oligomannose
glycans higher than (Man)6GlcNAc, has been found to be an agglutinating agent
in rabbit erythrocytes as well as a powerful murine T-cell mitogen [150, 151].
In vivo studies with antiviral lectins has also identified challenges. ConA,
which has an anti-HIV-1 50% effective concentration (EC50) of approximately
98nM has significant in vivo toxicity [25]. ConA binds high-mannose type, hybrid
type and biantennary complex type N-glycans [152] and has been observed to
strongly agglutinate many cell types, as well as has been identified as having
fetal development toxicity in rats [153]. Further, investigation into ConA’s toxicity
identified ConA as inducing focal hepatic necrosis, lymphoid atropy, and vascular
endothelial damage at a 200-800 µg dosage in mice [154, 155].
In addition to potential toxicities associated with carbohydrate binding
activity, lectins may induce allergic reactions and anaphylaxis. Immune reaction
to exogenous proteins are not uncommon [156]. The largest potential threat is
anaphylaxis [82]. However, other, less life threatening immune reactions may
also occur, such as the generation of neutralizing antibodies [82].
Protein therapy-induced anaphylaxis has been observed with approved
therapeutics Rituximab, Omalizumab, and alpha galactosidase A [157-160].
These therapeutics are testament to the idea that despite the risks, the benefits
of protein based therapy can weigh in favor of approval. Nonetheless, efforts to
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reduce the chance of lethal reactions continue. For example, efforts into structure
guided protein modifications to reduce immunogenicity have been theorized [161,
162]. These modifications would lessen the potential for immune system
recognition, thus reducing the possibility of an immune response [161, 162].

Griffithsin Structure and Mechanism of action
GRFT is an antiviral lectin derived from the red algae Griffithsia sp,
possessing a strong affinity for N-linked high mannose glycans [32, 33]. GRFT
forms ~25kDa domain swapped homodimers in solution, with the first 16 amino
acids of each monomer completing the B-prism fold of the other monomer [163].
These jacalin-like binding pockets are formed by 3, four stranded beta sheets,
with an internal symmetry. A total of 6 mannose binding sites have been
identified by X-ray crystallography of dimeric GRFT at 1.3A resolution [163, 164].
The six carbohydrate binding pockets are equally split, with three carbohydrate
binding pockets being located on opposite ends of the double-prism structure
[163]. Atomic resolution crystal structures of an engineered monomeric GRFT
have revealed that each monomer can bind to two different nonamannoside
molecules through all three carbohydrate binding sites [163, 165]. Further,
structural complexes of GRFT with saccharides have identified 3 virtually
identical active sites on each monomer consisting of a GGSGG motif [166]. Upon
dimeric folding, X-ray crystallography has also identified the geometries of the
binding sites as being equilaterally triangular in shape [164].
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In the case of HIV-1, GRFT’s inhibitory activity is associated to its binding
of the almost exclusively high-mannose glycans present on gp120 protein [13,
32]. Supporting this theory is the fact that lectin-resistant isolates of HIV have
reduced numbers of glycosylation sites [16]. Additionally, a loss in antiviral
activity was observed with monomerization of GRFT, suggesting that GRFT’s
ability to cross link virions or gp120 proteins is key to its antiviral activity[167].
This crosslinking of N-linked glycans present on the envelopes is thought to
inhibit structural transitions required for viral entry. GRFT has also been
observed to inhibit HIV-1 transfer from dendritic cells (DC) receptor DC-SIGN to
uninfected T-cells. To date, GRFT is the most potent antiretroviral drug of any
drug class for preventing transmission of cell-free and -associated HIV-1.
Prior work has suggested that GRFT can be cost effectively produced in
tobacco plants [168, 169]. Additionally, prior studies have suggested GRFT’s
weak immunogenicity and demonstrated low induction of inflammatory cytokines
and chemokines in animal models [33, 169]. These studies have confirmed
GRFT displays no human T-cell mitogenic activity, and unlike many other lectins
does not induce production of pro-inflammatory cytokines in treated human
peripheral blood mononuclear cells at >10,000 times antiviral concentrations [35,
169].
GRFT also has a notably broad spectrum of activity. Antiviral activity
against HCV [30, 170], HIV-1 [32, 169, 171], HIV-2 [171], and SARS-CoV [172]
has been documented. Unpublished studies have also demonstrated activity
versus influenza A virus, and several other enveloped viral pathogens (O’Keefe
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BR, unpublished). For many of these diseases, GRFT has a markedly low in vitro
inhibitory activity. Against HCV, GRFT’s EC50 has been found to be
approximately 13.9 nM [170]. Versus SARS-CoV, it has an EC50 of 48 nM. [163,
172]. However, in the case of HIV-1, Griffithsin has an in vitro EC50 in the mid
picomolar to low nanomolar range [16, 32, 169].
General studies into GRFT’s systemic tolerance have also been
encouraging. We observed GRFT to be tolerable during a 10 day chronic dosing
regimen [34]. This tolerability, seen in both mice and guinea pigs
subcutaneously dosed with GRFT raises the potential for short term usage of
GRFT as a prophylactic treatment. Further, continued antiviral activity against
HIV-env pseudoviruses and a long serum persistence of GRFT were observed
[34]. These factors would support in vivo administration of GRFT in an exposure
setting wherein amelioration or prevention of establishment of infection were the
goal of therapy.
GRFT’s antiviral activity has also been observed both ex vivo and in vivo.
HIV-1 infection of human cervical explants has been prevented by topical
application [169]. In vivo challenges in mice have also been positive, with activity
versus: SARS-CoV (intranasal treatments) [172]; Japanese encephalitis virus
(JEV) (intraperitoneal treatment) [173]; and HCV (subcutaneous treatment mouse-human chimeric liver models) [30, 170].
With the short term tolerability of GRFT administration established, as well
as the potential for viral inhibition in vivo, it is possible that GRFT may be useful
in established infections. Despite the advent of modern HAART, which can
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suppress viral replication below currently detectible limits, new therapies are
constantly needed. HIV’s propensity for mutation under drug pressure translates
into an eventual viral breakthrough. Further, as mentioned previously, during
times of immune activation-such as a cold or infection, viral “blips” may occur in
which a person with a previously undetectable viral load displays a detectable
viremia[94, 103]. Accordingly, agents which could further reduce the chance of
drug resistant isolate proliferating may assist in maintaining viral undetectable
viral loads – a key factor in infectiousness. Further, given the current window of
opportunity for preventing establishment of a productive infection, additional
drugs that could be used for PrEP or PEP may have utility in both occupational
and nonoccupational settings. However, for GRFT’s usage in established
infections, long term systemic impacts, including potential immune activation
which may trigger low level viremia, a neutralizing antibody response, or
systemic toxicity, need to be assessed.
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OVERARCHING HYPOTHESIS
This work presents a compilation of work investigating the overarching
hypothesis that GRFT is a candidate for systemic antiviral therapy. However, a
number of unknowns currently exist. In Chapter 2, we review the animal studies
which laid the foundation for the present evaluation of GRFT’s systemic
tolerance. In Chapter 3, we examine the practical pharmacokinetics of GRFT in
Sprague Dawley rats and its potential impact upon method of administration,
timing of dosage, and method of excretion. In Chapter 4, we examine the
tolerability of sub-chronic dosing of GRFT in Sprague Dawley rats, with an
immune response primed by pre-immunization with GRFT as well as passive
immunization with anti-GRFT IgG. Finally in Chapter 5, we examine GRFT’s
biochemical interactions through Differential Scanning Fluorometry and Affinity
Purification, as well as examination of the effects on endogenous proteome
interactions through Differential Scanning Calorimetry. The findings in this
Dissertation lay a foundation for further study to validate GRFT’s usage as a
systemic antiviral therapeutic or prophylactic.
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Figure 1.1 N-linked Glycans – structural arrangement of subtypes. Schematics
illustrating examples of different N-linked glycans. Oligommanose Glycans –
Man9 (A) and Man5 (B) present exclusively mannose termini. Hybrid Glycans
(C) present both mannose termini and GlcNAc termini. Complex glycans (D)
have no mannose termini.

23

CHAPTER 2
ACTIVITY AND EFFECT OF SUBCUTANEOUS TREATMENT WITH THE
BROAD SPECTRUM ANTIVIRAL LECTIN GRIFFITHSIN IN TWO
LABORATORY RODENT MODELS1
INTRODUCTION
The glycan structures displayed on envelope glycoproteins frequently play
important roles in virus transmission and entry into target cells [40]. Viruses that
establish chronic infections, such as HIV and HCV, display a dense shield of
oligomannose glycans that also assist the pathogen in immune evasion, both
through the display of “self”-like epitopes as well as by induction of
immunosuppressive innate immune responses [13, 17, 19, 51, 60]. Antiviral
compounds that target envelope glycoproteins are classified as “carbohydrate
binding agents” (CBA), and generally encompass lectins and non-peptidic
antibiotics such as pradimicin A and –S and benanomicin A (reviewed by
Balzarini [14]). Several different lectins from natural sources show significant
antiviral activity in vitro and have been proposed as antiviral prophylactic and
1

Antimicrob Agents Chemother. 2014 Jan;58(1):120-7.
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therapeutic compounds. While there is a plethora of publications in the scientific
literature showing in vitro antiviral activity of CBA against a broad array of
enveloped viruses, most in vivo studies on safety and efficacy of this class of
compounds are in pre-exposure prophylaxis models. However, two important
studies demonstrate the potential of antiviral therapy with lectins. Smee et al.
[28] demonstrated that post-exposure treatment with the antiviral lectin
cyanovirin-N, which targets an α-(1–2)-linked mannobiose substructure on
oligomannose glycans, showed significant survival benefit 6 hours after infection
in a murine influenza model. A recent study by Michelow and colleagues [29]
demonstrated that high dose therapy with human mannose binding lectin (MBL),
an endogenous C-type lectin that recognizes glycan structures including
mannose, glucose and fucose on the surface of pathogens, could ameliorate
Ebola virus infection in a murine model. Despite their demonstrated antiviral
activities, the fact that many natural product lectins have significant in vitro and in
vivo toxicity, acting as non-specific T-cell stimulants and red blood cell
agglutinating agents, has limited their development as antiviral therapeutics.
However, not all antiviral lectins are toxins and not all antiviral lectins have cell
agglutinating activity.
Griffithsin is a 12.77 kDa red algae derived lectin, that binds the terminal
mannose residues on the asparagine (N)-linked Man5-9GlcNAc2 structures that
comprise the vast majority of N-linked glycans in the HIV-1 glycan shield [32,
163-165]. GRFT displays no human T-cell mitogenic activity, and unlike many
other lectins does not induce production of pro-inflammatory cytokines in treated
25

human peripheral blood mononuclear cells [35, 169]. In collaborative studies, we
have shown that GRFT has broad spectrum antiviral activity against HIV-1 [32,
169, 171], HIV-2 [171], HCV [30, 170], an array of pathogenic coronaviruses,
including SARS-CoV [172], in addition to influenza A virus, and several other
enveloped viral pathogens (O’Keefe BR, unpublished). The in vitro inhibitory
activity (EC50) of GRFT against HIV-1 is in the mid picomolar to low nanomolar
range, for most isolates [16, 32, 169]. GRFT has EC50 against HCV (13.9 nM)
[170] and SARS-CoV (48 nM) [163, 172]. There is a growing body of published
evidence that GRFT also has antiviral activity ex vivo as well as in vivo: topical
application of GRFT prevents HIV-1 infection of human cervical explants [169];
intranasal treatments with GRFT prevents disease in mice challenged with
SARS-CoV [172]; intraperitoneal (IP) treatment with GRFT prevents Japanese
encephalitis virus infection in mice [173]; and subcutaneous treatment with GRFT
shows some efficacy against HCV challenge in a mouse-human chimeric liver
models [30, 170]. The JEV and HCV studies demonstrated that GRFT is
relatively well tolerated by mice exposed to the drug systemically at 5 mg/kg
doses, but did not report a comprehensive assessment of GRFT safety as a
potential systemic antiviral treatment. Here, we report that minimal toxicity is
induced by a range of subcutaneous doses of GRFT in two rodent species. The
drug was systemically distributed, and accumulates to high levels in the serum
and plasma after subcutaneous delivery. Furthermore, we demonstrated that
serum from GRFT treated animals retained anti-viral activity against HIV-1
enveloped pseudoviruses in a cell-based neutralization assay. Overall, these
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findings support further investigation into GRFT’s potential as a systemic antiviral
therapeutic agent against enveloped viruses including HIV-1.
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MATERIALS AND METHODS
Lectin reagents
Recombinant GRFT was produced in Nicotiana benthamiana plants as described
previously, purified to >99% purity, and formulated in phosphate buffered saline
(PBS), pH 7.4 [169]. Phytohemagglutinin A (PHA) was purchased from Sigma.
Animal housing and care
6-8 week-old female BALB/c mice (Jackson Laboratory) and Hartley guinea pigs
(Cavia porcellus, Charles River Laboratories) were housed in a temperature- and
humidity-controlled room with an alternating light/dark cycle of 12h, with standard
diet and water ad libitum. All experimental procedures were approved by the
University of Louisville’s Institutional Animal Care and Use Committee.
Mouse treatments and sample collection
To evaluate effects of a single high dose of GRFT, mice were injected
subcutaneously with 50 mg/kg GRFT (n = 30) or PBS (n = 15). At 1, 7, and 14
days post-treatment 10 mice treated with GRFT and 5 control animals were
sacrificed and blood was collected by cardiac puncture. Kidneys, livers, and
spleens were excised. For chronic administration, mice were treated with 10
mg/kg GRFT (n = 15) or PBS (n = 15) daily for 14 days. Each group was further
subdivided into 3 groups of 5 mice each. Blood was collected from the
submandibular vein every other day, alternating between subgroups. Animals
were sacrificed on day 14 (9 mice per treatment group), day 16 and day 21 (3
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mice per treatment group at each time point), and the samples collected as
outlined above.
Guinea pig treatment and sample collection
For chronic administration in guinea pigs, two studies were conducted at different
times. In the first experiment, 10 mg/kg GRFT (n=12) or 1 ml/kg PBS (n=6) was
subcutaneously administered daily for 10 days. The second experiment was
similar to the first, except for the number of animals (GRFT, n=10; PBS, n=6).
Half of the animals in each group were sacrificed on day 11 after cardiac
puncture exsanguination under isoflurane anesthesia, and the remaining animals
were euthanized on day 15. Blood and organs were collected at sacrifice.
Extraction of GRFT from mouse organs
100-500 mg pooled organ tissues were homogenized in 1 ml PBS supplemented
with complete, EDTA-free Protease Inhibitor Cocktail (Roche) and the samples
cleared by a series of two centrifugations steps at respectively 10,000 and
15,000 x g for 10 min each. The supernatants were stored at - 20˚C until use.
GRFT capture immunoassay using the HIV-1 envelope glycoprotein gp120
To detect trace amounts of GRFT present in serum and plasma, and in
homogenized organ tissues, we used a HIV-1 gp120 binding ELISA as previously
described [35] with a few modifications. Briefly, Maxisorp plates (Nunc) were
coated with 25 ng purified gp120 (Protein Sciences) and incubated overnight at
4oC. Plates were blocked with 3% (w/v) Bovine Serum Albumin (BSA) in PBS
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containing 0.05% Tween 20 (PBS-T). Samples were diluted 1:10 in blocking
buffer and were incubated at RT for 1 hour. Serial dilutions of purified GRFT
were run in parallel to generate a standard curve. The gp120-bound GRFT was
detected by rabbit anti-GRFT antiserum (1:25,000) followed by HRP-conjugated
goat anti-rabbit IgG (1:10,000). Plates were developed with SureBlue TMB
Microwell Peroxidase Substrate, and reactions were stopped with 1N H2SO4.
Absorbance readings at 450 nm and 570 nm were measured using a BioTek
Synergy HT plate reader.
Evaluation of Anti-HIV Activity.
HIV-1 neutralization activity of heat-inactivated serum or plasma was measured
using pseudovirus neutralization assays as previously described [174]. Briefly,
molecularly cloned DU156 env-pseudotyped virus particles were generated by
transfection of 293T cells and titrated in TZM-bl cells. Antiviral activity was
measured as a function of luciferase reporter gene activity. ID50 values were
defined as the sample dilution required to reduce luminescence by 50% in
comparison to wells with no sample added (within the linear range of the assay).
Hematology parameters and Serum Chemistry.
A complete blood count (CBC) was run for guinea pig samples using a
Hemavet® 950 (Drew Scientific) standardized for guinea pig blood. The following
parameters were quantified in potassium-EDTA anticoagulated whole blood: red
blood cells (RBC; 104/µl), total and differential leukocyte count (neutrophils,
lymphocytes, monocytes, eosinophils, and basophils as 10 3/µl or %), hemoglobin
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concentration (HGB; g/dl), hematocrit (HCT; %), mean corpuscular volume
(MCV; fl), mean cell hemoglobin (MCH; pg), mean cell hemoglobin concentration
(MCHC; g/dl), red cell distribution width (RDW; %), platelets (PLT; 104/µl), and
mean platelet volume (MPV; fl).
In the first guinea pig experiment levels of the following serum chemistries were
assessed and the differences analyzed by two-way ANOVA: serum albumin
(Alb), alkaline phosphatase (ALKP), amylase (Amy), alanine aminotransferase
(ALT), blood urea nitrogen (BUN), calcium (Ca), cholesterol (Chol), creatinine
(Creat), globulin (Glob), glucose (Glu), phosphorus (Phos), total bilirubin (TBil),
and total protein (TP). Based on the results obtained, we decided to further
measure the effect of GRFT on selected markers including serum albumin,
alkaline phosphatase, and amylase in the second experiment using a VetTest®
Chemistry Analyzer (IDEXX Laboratories)
Hemagluttination assays.
Guinea pig, sheep, and human blood (Innovative Research), and blood collected
from untreated mice was washed and resuspended at a final concentration of 12% (v/v) in 1X PBS containing 3 g/L BSA and 1 g/L sodium azide. PBS, PHA, or
GRFT were mixed with an equal volume of erythrocytes in a 96-well round
bottom plate. The plate was incubated for 1 hr at RT, followed by overnight
incubation at 4°C. Finally, wells were dried and hemagglutination activity was
determined by visual examination.
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Statistical Analysis.
Statistical analysis was conducted using Graph Pad Prism 5 and SAS software
version 9.3. Because of the stratification by guinea pig study, day of sacrifice
and treatment group, it was decided to increase statistical power by using all the
data from both studies. Three-way ANOVA [175] analysis was utilized, which
allowed testing for treatment effect while at the same time adjusting for
differences between the two studies and the days of sacrifice. For initial
univariable analysis, the two-sample t-test [176] or Wilcoxon rank sum test [177]
was used to test for differences between study, day of sacrifice, and treatment.
For data sets collected in only one guinea pig study – such as weight change and
non-selected serum chemistries, a two-way ANOVA was utilized. A p-value <
0.05 was deemed significant.
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RESULTS
Griffithsin serum concentrations.
Plasma samples collected from mice injected with a single high dose of 50 mg/kg
GRFT showed up to 4 nM GRFT (4 nM equals 51.08 ng/ml) in animals sacrificed
one day post treatment (Figure 2.1A). These levels decreased considerably to
less than 0.5 nM by day 7, and persisted through day 14.
In chronically dosed mice, plasma concentrations of GRFT peaked at 25 nM
(Figure 2.1B) by day 11, followed by a gradual decrease in detectable GRFT
even with subsequent treatments. This trend continued throughout the recovery
time. Notably, concentrations of GRFT persisted in the plasma at levels of
approximately 4 nM after a week of recovery (Figure 2.1B). GRFT
concentrations in sera from chronically treated guinea pigs were similar to that of
chronically treated mice, with mean concentrations of 36 nM at day 11 and 11.36
nM at day 15 (Figure 2.1C).
Anti-HIV Activity of plasma and serum.
Plasma samples collected from mice treated with a single dose of 50 mg/kg
GRFT neutralized HIV-1 pseudoviruses (Clade C primary sexually transmitted
isolate Du156) with a mean ID50 (dilution required for a 50% reduction in
luminescence versus controls) of 1500 on experimental day 2 (Figure 2.2A).
This neutralization activity decreased in samples obtained at days 8 (ID50 of 300)
and 15 (ID50 of 200). Plasma from chronically treated mice neutralized the HIV-1
Du156 pseudovirus with an ID50 value of approximately 800 (Figure 2.2B) at day
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14. After the 7 day recovery period, the ID50 values decreased to approximately
200. Serum samples collected from guinea pigs after chronic treatment with 10
mg/kg GRFT displayed a mean ID50 of approximately 3277 at day 11 and 576 at
day 15, respectively. The HIV-1 Du156 neutralization activity of guinea pig sera
correlated well with the concentration of GRFT detected in the serum; however,
the GRFT serum concentrations detected in mouse samples predicted only about
14-25% of the actual serum HIV-1 neutralization activity we observed, confirming
that additional non-specific HIV-1 neutralizing activities in mouse serum
contribute to the higher-than expected overall HIV-1 inhibitory activity in the
mouse sera.
GRFT distribution into tissues.
Organs from mice chronically treated with GRFT were harvested, and total
protein extracted. We measured the total amounts of GRFT that accumulated in
these tissues by gp120 binding ELISA. Figure 2.3 shows that GRFT
accumulated in all three organs assayed, with most GRFT accumulating in the
spleen. Non quantitative immunofluorescence studies detected GRFT in the
same organs (liver, kidney and spleen) harvested from treated guinea pigs (data
not shown).
GRFT is tolerated after subcutaneous administration
We studied the toxicity of GRFT in guinea pigs using several parameters
including mortality, behavior, animal body and organ weight changes, tissue
pathology, and changes in blood properties.
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All animals survived and no change in behavior was observed. Since the guinea
pigs used in this work were juvenile, we evaluated their overall fitness after
GRFT treatment using body weight as a surrogate marker. Animals were
weighed at day 1 and at time of sacrifice. Using a 2-way ANOVA to measure the
impact of treatment and time on bodyweight gains, we found that GRFT
treatment resulted in significantly less bodyweight gain in comparison with PBS
treated controls (p=0.0011, Figure 2.4)
Liver, kidney, and spleen weights measured at termination were normalized to
total body weights and compared to time matched controls. A statistically
significant increase of the normalized weights of guinea pig livers and spleens
was observed for GRFT treated animals (p=0.008 and 0.005, respectively, Figure
2.5). Tissue sections from guinea pigs in the second experiment were stained
with hematoxylin and eosin and evaluated in a blinded fashion by a veterinary
pathologist (O.F.). No distinct pathologies were observed as a result of GRFT
treatment. Of all CBC parameters tested, a statistically significant difference was
observed only in Red Blood Cell Width (RDW) (p=0.016, Table 2.1). Of note the
RDW values obtained for GRFT-treated animals were still within the normal
physiological range described for guinea pigs (38).
In addition to CBCs, serum chemistries were examined. When data collected
from both experiments were combined for analysis, a statistically significant
increase was observed for Alkaline Phosphatase after GRFT treatment
compared with controls (p=0.001, Figure 2.6). There were no statistically
significant differences between the GRFT treated group and the PBS control
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group in the remaining serum chemistry when examined by 2-way ANOVA
(Figure 2.6).
Since many natural product lectins cause hemagglutination, we investigated
GRFT’s hemagglutination activity in several species. Blood samples from guinea
pig, mouse, sheep, and human were tested. Interestingly, only red blood cells
from guinea pigs were affected by GRFT—at concentrations over 5 µg/ml (Fig.
2.7). As expected, the vehicle (PBS) did not show any hemagglutination activity
on erythrocytes, and the known hemagglutinating agent PHA demonstrated
activity at concentrations of 5 µg/ml and above for all species tested.
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DISCUSSION
In this study, we demonstrate that GRFT persists in serum and plasma of
laboratory rodents at concentrations well above the EC50 described for several
known enveloped viruses [23, 32, 170, 178] after subcutaneous administration.
Although decreasing in concentrations after final administration, functionally
active concentrations of GRFT, as determined by gp120 binding ELISA, remain
in circulation for many days after treatment cessation both in single and chronic
dosing regimens. These findings support further investigations of the utility of
GRFT in treatment of both acute and chronic viral infections.
Every drug candidate must show a favorable safety profile to advocate for
its further development. Previously, we demonstrated that GRFT was devoid of
any mitogenic and cytotoxic activity, was unable to induce cell mediators of
inflammation, and had only minimal off target effects on human cells [35]
corroborating with other works [32, 169] and unlike other anti-HIV lectins
including CVN and ConA [149, 179]. In the present in vivo studies GRFT did not
alter experimental animal behavior and no animal died as a result of treatment.
Using juvenile animals, we did notice that guinea pigs treated with GRFT gained
weight significantly slower than those injected with PBS. This is not the case
when adult mice are treated s.c. with GRFT (manuscript in preparation). Organ
toxicity was also assessed both by measuring weights and histopathology. While
liver and spleen percentages displayed a statistically significant increase in
comparison with controls, histopathological examination of the organs from
GRFT treated animals did not show any pathology.
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When a complete blood count was performed and serum chemistries
analyzed, we observed that most of the parameters were not significantly
changed as a result of GRFT treatment. The only exception was RDW. Although
significantly different from PBS controls, RDW values obtained from GRFTtreated animals remained within the normal range described for guinea pigs. In
serum chemistries, alkaline phosphatase was significantly elevated in GRFT
treated guinea pigs. Whether this elevation is related to the increased liver mass
to body weight ratio seen with GRFT-treated animals is yet to be determined
since the alkaline phosphatase isotype was not determined.
As a xenogeneic protein, a key concern is a possible immune response to
GRFT which could lead to anaphylaxis [180]. Our data showing treatment
associated increases in spleen and liver mass to body weight ratios is suggestive
of a nascent immune response to GRFT treatment. However, we were unable to
detect anti-GRFT antibodies in sera from these treated animals, probably
reflective of the short duration of these studies. Although GRFT is a relatively
weak immunogen, we are able to raise high titer antibodies in animals immunized
with GRFT in the presence of adjuvant; these hyperimmune sera are binding, but
non-neutralizing (data not shown). Immunogenicity of biologic drugs is a widely
acknowledged issue, and our data suggest that future efforts to de-immunize
GRFT by structure-guided elimination of T-cell epitopes [161, 162], may be
necessary before the product is used for chronic treatment of viral infection in
humans. Lectins are well known for their mitogenic and agglutinating properties
[149, 151, 179, 181-183] which prevent their use as therapeutics. We have
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addressed the mitogenicity concern by showing previously that GRFT lacks Tcell mitogenic activity [35]. Here, we demonstrated that GRFT does not
agglutinate red blood cells from several species including human, mouse and
sheep. However, we observed that guinea pig erythrocytes were agglutinated by
GRFT at high concentrations. The cause of this discrepancy is unclear, but may
well be associated with the treatment-associated increase in red blood cell width
we observed. We conclude that the preliminary toxicity profile of GRFT is
acceptable and favors its further development in antiviral prophylaxis and
therapy.
GRFT is currently under development as a topical microbicide as well as a
broad spectrum antiviral. However GRFT is not systemically bioavailable after
topical administration (our unpublished observations), so parenteral
administration is probably necessary to achieve sufficient drug in systemic
concentrations necessary for effective suppression of viral replication. Our data
confirm that subcutaneous administration of GRFT is a viable and efficient way
to get the drug into circulation to allow a sustained pharmacodynamic effect
[184]. Our data support the results of published studies on GRFT prophylactic
efficacy in murine models of HCV and JEV infection[30, 31, 173]. Both studies
found that GRFT effectively suppressed viral replication when administered at a
5 mg/kg dose, either subcutaneously or intraperitoneally. We are currently
studying whether administrations of GRFT, under the 10 mg/kg dosage, are
sufficient to maintain drug concentrations at potentially therapeutic levels. There
is substantial precedent for patient self-administration of drugs via the
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subcutaneous route; indeed the peptide HIV fusion inhibitor Enfurtide (T-20) is
dosed in this fashion. Our data confirm that we can achieve HIV-1 Du156 50%
serum neutralization indices in excess of 500 after 14 daily doses of GRFT at 10
mg/kg (Fig. 2.2), which should be sufficient to inhibit HIV replication, and perhaps
promote viral evolution towards enhanced humoral antibody suppression[14,
151, 184]. These levels were also more than sufficient to prevent JEV and HCV
infection in respective mouse models [16, 31]
Under selection pressure with CBA, susceptible viruses may evolve
towards resistance through loss of key N-linked glycosylation sites [25, 185-188].
Interestingly, in the case of HIV-1, CBA resistance correlates with reduced viral
fitness and enhanced susceptibility to neutralizing antisera [14, 186, 188].
Consequently, it has been suggested that CBA therapy of chronic viral infections
like HIV-1 and HCV may promote viral evolution towards resistance to the CBA
concomitant with enhanced susceptibility to host immune control. This concept
of CBA-mediated immunotherapy holds considerable appeal as a method to
promote durable immune control, and perhaps even eradication of HIV infection
[14]. Given GRFT’s antiviral activity in the mid picomolar range, and our data
here that show that the drug accumulates to relevant therapeutic concentrations
which are tolerated with minimal toxicity, GRFT is a strong candidate for further
experimental testing of this idea first put forward by Dr. Balzarini and colleagues
[14].
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Figure 2.1 Griffithsin concentrations in plasma and serum samples. Data were
obtained from mouse plasma after a single high-dose administration of 50 mg/kg
GRFT (A), a chronic daily administration of 10 mg/kg GRFT (B), and from guinea
pig serum after 10 daily administrations of 10mg/kg GRFT (C). PBS was
administered to control animals and bars indicate mean group concentration.

41

Figure 2.2. Antiviral activity of samples collected from GRFT treated animals.
HIV-1 env- pseudovirus neutralization activity was assessed for mouse plasma
after a single high dose administration of 50 mg/kg GRFT (A) and expressed as
ID50. The ID50 values were obtained for samples from guinea pigs and mice
chronically treated with 10mg/kg GRFT (B). Control animals were treated with
PBS bars indicate mean group concentration. 1-way ANOVA significance
(p<0.05) is indicated by (*).
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Figure 2.3. Quantitation of GRFT in mouse organs. Pooled Protein samples
were extracted from kidneys, livers, and spleens after a chronic subcutaneous
administration of GRFT or PBS and GRFT was detected using a gp120-binding
ELISA.
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Figure 2.4. Guinea pig body weight gain as an indicator of overall health. Body
weights were measured on experimental Day 1 and on the termination day (Day
11 or Day 15). Significance (p<0.05) is indicated by (*).
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Figure 2.5. GRFT does not affect guinea pig organ weights. Liver (A), kidney (B),
and spleens (C) weights were measured relatively to body weight at sacrifice.
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Cell Type
Leukocyte

Parameter

Unit

PBS (n=3)

Day 11
GRFT (n=5)

PBS (n=3)

Day 15
GRFT (n=5)

WBC
NE
LY
MO
EO
BA

k/µl
k/µl
k/µl
k/µl
k/µl
k/µl

4.92 ± 2.43
2.30 ± 1.46
2.49 ± 1.11
0.09 ± 0.10
0.03 ± 0.02
0.00 ± 0.01

2.15 ± 0.23
0.96 ± 0.13
1.14 ± 0.28
0.03 ± 0.03
0.02 ± 0.01
0.00 ± 0.00

4.35 ± 1.28
1.67 ± 0.45
2.60 ± 0.89
0.07 ± 0.03
0.02 ± 0.01
0.00 ± 0.00

2.90 ± 1.36
1.01 ± 0.42
1.82 ± 0.99
0.06 ± 0.04
0.01 ± 0.02
0.00 ± 0.00

RBC
Hb
HCT
MCV
MCH
MCHC
RDW

M/µl
g/dl
%
FL
pg
g/dl
%

4.30 ± 0.06
12.23 ± 0.64
38.30 ± 2.31
88.97 ± 4.73
28.43 ± 1.33
31.97 ± 0.25
13.83 ± 1.43

4.12 ± 0.18
11.64 ± 0.46
36.12 ± 1.47
87.58 ± 1.29
28.26 ± 1.52
32.26 ± 1.33
12.92 ± 0.73

4.75 ± 0.21
13.10 ± 0.46
41.57 ± 1.76
87.53 ± 1.70
27.63 ± 0.61
31.50 ± 0.26
14.13 ± 0.29

4.37 ± 0.22
12.22 ± 0.61
39.52 ± 1.94
90.40 ± 0.52*
27.96 ± 1.04
30.94 ± 1.11
12.66 ± 0.70*

PLT
MPV

k/µl
fL

595.33 ± 54.31
4.40 ± 1.14

628.60 ± 44.77
3.92 ± 0.23

677.33 ± 11.93
3.57 ± 0.12

659.00 ± 34.26
3.84 ± 0.24

Erythrocyte

Thrombocyte

Table 2.1. Hematological profile for guinea pigs after chronic treatment with
GRFT. Data represent the mean values +/- standard deviation for white blood
cells (WBC), neutrophils (NE), lymphocytes (LY), monocytes (MO), eosinophils
(EO), basophils (BA) , red blood cells (RBC), hemoglobin (Hb), hematocrit (HCT),
mean corpuscular volume (MCV), mean cell hemoglobin (MCH), mean cell
hemoglobin concentration (MCHC), red cell distribution width (RDW), platelets
(PLT), and mean platelet volume (MPV). Significance (p<0.05) is indicated by
(*).

46

Figure 2.6. Serum chemistry data for guinea pigs after chronic treatment with
GRFT. Levels of Serum Albumin (A), Alkaline Phosphatase (B), and Amylase
(C) were obtained from GRFT or PBS treated animals at sacrifice. Bars indicate
mean group concentration.
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Figure 2.7. Hemaggluttination activity of GRFT. A wide range of GRFT
concentrations (5 µg/ml equals 391 nM) was used to examine GRFT’s potential
hemagluttination activity on erythrocytes from multiple species including sheep
(A), Guinea pig (B), Human (C), and Mouse (D). PHA (5 µg/ml) and PBS were
used as positive and negative controls, respectively.
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CHAPTER 3
THE PHARMACOKINETCIS OF THE ANTIVIRAL LECTING GRIFFITHSIN
INDICATED MULTIPLE POTENTIAL USES AND CHALLENGES
INTRODUCTION
Various lectins, carbohydrate binding proteins that bind specific glycan
structures, are important components of many organisms’ innate pathogen
defense system. Several lectins isolated from natural sources are known to
inhibit microbial and viral infections in vitro and in vivo [29, 31, 37, 142, 189, 190].
Griffithsin, derived from the red alga Griffithsia, is a dimeric lectin with a total of 6
binding sites capable of binding terminal oligomannose residues on asparagine
(N)-linked Man5-9GlcNAc2 structures[32, 163-166]. Mannose terminal glycan
structures appear to comprise a significantly greater proportion of glycans on
pathogen surfaces than in mammalian host cells. In fact, oligomannose
structures comprise the vast majority of N-linked glycans in the HIV-1 glycan
shield [13, 60], where they assist in the virus’s evasion of immune surveillance
[40]. Multiple studies have described Griffithsin’s HIV-1 neutralization EC50 in
vitro as being within the mid picomolar range [16, 32, 169]. GRFT also exhibits
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nanomolar activity against several other enveloped viruses such as HCV, HSV-2,
SARS CoV, and JEV, amongst others[23, 31, 36, 173]. GRFT prevents viral
infection in vitro by binding the envelope oligomannose glycans, and thereby
occluding functionally important domains of the viral envelope protein, preventing
interactions with cell-surface receptors, or otherwise impeding structural
transitions necessary to effect infection. In the case of HSV-2, GRFT may also
act by inhibiting virus egress and spread post-infection[36]. Topical application of
GRFT prevents HIV-1 infection of human cervical explants [169], and inhibits
viral spread in murine HSV-2 vaginal challenge[36].
In preexposure prophylaxis models, GRFT has displayed antiviral activity
against HSV-2, SARS-CoV, and HCV [23, 31, 36, 171, 191].

In examining

GRFT’s systemic chemotherapeutic potential, our previous studies have shown
that in two rodent models, GRFT is tolerable in short term subcutaneous dosing,
while retaining anti-viral activity in serum [34]. This tolerability profile, retained
antiviral activity, and broad spectrum activity against susceptible viruses further
supports the study of GRFT as a systemic chemopreventative or
chemotherapeutic.
While GRFT has initially been evaluated as a potential topical microbicide,
its pharmacokinetic profile – which could limit its practical utility as
chemotherapeutic or chemopreventative - is currently unknown. Given GRFT’s
observed resistance to low pH and a number of proteases[192], we hypothesized
that GRFT may have some degree of oral bioavailability. We compared the
concentration of GRFT in serum from treated animals following intravenous,
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subcutaneous, and oral dosing, and report that the pharmacokinetic profile of
GRFT can vary greatly depending on method of administration. Additionally, we
report a small fraction of oral dosage of GRFT formulated in PBS passes through
the digestive tract and retains anti-viral activity in fecal material. Further, we
found that after both single dose and 10 day chronic oral administration, GRFT
was undetectable in serum and urine, indicating that GRFT is either not
systemically absorbed to a detectible degree upon ingestion or inactivated during
the absorption process. Accordingly, the method of administration should be
considered when researching the usage of GRFT as an orally dosed preexposure prophylactic, or intravenously or subcutaneously-dosed systemic
therapeutic or chemopreventative.
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MATERIALS AND METHODS

Lectin reagents

Recombinant GRFT produced in Nicotiana benthamiana plants as
described previously [169] was purified to >99% purity in phosphate buffered
saline (PBS), pH 7.4 with less than 0.05 Endotoxin Units (EU) per milligram.

Animal housing and care

250g

Sprague

Dawley

Rats

(Rattus

norvegicus,

Charles

River

Laboratories) were housed in a temperature- and humidity-controlled room with
an alternating light/dark cycle of 12h, with standard diet and water ad libitum. All
animal procedures were approved by the University of Louisville’s Institutional
Animal Care and Use Committee.

Pharmacokinetic Study Dosing and Sample Collection

250g Sprague Dawley rats were procured from Charles River with
indwelling femoral vein catheter. Rats were weighed and treated with a single
dose of either 10mg/kg or 20mg/kg GRFT. For intravenous treatment, indwelling
catheters were checked for patency and either 10mg/kg or 20mg/kg GRFT was
infused into the catheter over a 15 second period. Catheters were then flushed
by PBS infusion of 3 times the catheter volume and filled with heparinized
glycerol (Braintree Scientific) before reinsertion of the catheter plug. For
subcutaneous treatment, 10 mg/kg or 20 mg/kg GRFT was injected under the

52

skin between shoulders. For oral dosing treatment, 2.5 mg of GRFT formulated
to a final volume of 1 ml was dosed via gastric lavage.

In intravenously and subcutaneously dosed animals, approximately 150 µl
of blood was drawn via indwelling femoral catheter at the following time points
after GRFT administration: 15 minutes, 30 minutes, 1 hour, 2 hour, 4 hour, 8
hour, 24 hour, and 48 hours (sacrifice). To capture later time points, an
additional cohort of animals had 150ul blood drawn at 72 and 96 hours post
dosage. Orally dosed animals had 150µl of blood drawn at the following time
points post administration: 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours,
4 hours, 6 hours, 24 hours and 24 hours. All animals were sacrificed by CO 2
asphyxiation followed by thoracotomy at the conclusion of the study.

Chronic Oral Dosing Treatment and Sample Collection

18 rats were treated daily with either 1ml PBS (n=6), 5 mg GRFT (n=6, 1
ml dosing volume), or 10 mg GRFT (n=6, 1 ml dosing volume) for a period of 10
days via gastric lavage. On treatment day 5, blood samples were drawn via
lateral tail vein approximately 3 hours after oral dosing. On day 10, animals were
treated, and approximately 3 hours after treatment, animals were sacrificed via
CO2 asphyxiation followed by thoracotomy. Blood was drawn by cardiac
puncture after euthanasia. Urine was taken at selected time points after oral
dosing.
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Active Mass Balance Rat Treatment and Sample Collection.

10 rats were treated with a single dose of either 2.5 mg GRFT (10mg/ml)
through either intravenous indwelling catheter or subcutaneous dose. 5 rats
were treated with 2.5 mg of GRFT (1 ml dosing volume) via gastric gavage.
Post dosage, animals were placed in metabolic cages and urine was collected at
the following time points after treatment: 4 hours, 8 hours, 12 hours, 20 hours,
and 48 hours. Fecal pellets were collected at 24 and 48 hours. Urine volume and
fecal pellet mass was quantitated for mass balance calculation.
Fecal Pellet Collection and Extract preparation – Chronic Oral Treatment

Fecal pellets from treated animals were obtained at 8 and 24 hours after
initial treatment and at selected days thereafter by randomly drawing 6 dried
pellets from animal cage bedding. Briefly, for fresh fecal pellets not requiring
additional PBS for rehydration, 1ml of PBS was added per 1 gram of pellets in a
1.5ml Eppendorf tube. For dried fecal pellets requiring rehydration 2ml of PBS
per were added per 1 gram of pellets in an Eppendorf tube. Pellets were allowed
to absorb the PBS for 15-30 minutes before crushing and mixing. After crushing
and mixing, the resulting fecal slurry was centrifuged at 1000g for 5 minutes and
supernatant removed. Supernatant was spun again to pellet and remove and
debris and final extract supernatant was removed and aliquoted for GRFT
concentration determination and anti-HIV activity testing. Fecal extract samples
were pooled by combining equal volumes of extract from each cage within the
applicable treatment group.
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Fecal pellet extracts from chronically treated animals underwent additional
processing to further remove contaminants before HIV-1 pseudovirus
neutralization assays. Samples were sterilized and filtered using Costar Spin-X
centrifuge Tube Filters with a 0.22 µm Cellulose acetate filter. After filtration,
samples were then dialyzed in a dialysis cassette with a 2000 molecular weight
cut off membrane in PBS for 24 hours at 4ºC.

Extracts for mass balance experiments were prepared by desiccation and
rehydration of fecal pellets. After overnight desiccation in a vacuum centrifuge,
pellets were pulverized into powder using a commercial coffee grinder. Pellet
extracts were formulated using 0.5g of dried powder and 2 ml of PBS. After
rehydration the resulting fecal slurry was thoroughly mixed and centrifuged at
1000g for 5 minutes and supernatant removed. Supernatant was spun again to
pellet and remove and debris and final extract supernatant was removed and
aliquoted for GRFT concentration determination.

GRFT capture immunoassay using the Influenza HA

To detect trace amounts of GRFT present in serum and fecal extracts, we
used an ELISA as previously described with modifications [34]. Briefly, Maxisorp
plates (Nunc) were coated with 10 µg/ml purified influenza hemagglutinin (HA) in
PBS (Kentucky Bioprocessing) and incubated overnight at 4oC. Plates were
blocked with ~2.5% (w/v) Bovine Serum Albumin (BSA) in PBS containing 0.05%
Tween 20 (PBS-T). Samples were diluted in blocking buffer and were incubated
for 1 hour at RT. Serial dilutions of purified GRFT were run in parallel for
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standard curve generation. Active, HA-bound GRFT was detected by rabbit antiGRFT antiserum (1:25,000) followed by HRP-conjugated goat anti-rabbit IgG
(1:10,000). Plates were developed with SureBlue TMB Microwell Peroxidase
Substrate, and reactions were stopped with 1N H2SO4. Absorbance readings
were measured at 450 nm and 570 nm using a BioTek Synergy HT plate reader.

Evaluation of Anti-HIV Activity of Fecal Extracts.

HIV-1 neutralization activity of fecal pellet extracts from pooled, chronically
treated animals was measured using pseudovirus neutralization assays as
previously described [174]. Briefly, DU156 env-pseudotyped virus particles were
generated by transfection of 293T cells and titrated in TZM-bl cells. Antiviral
activity, a function of luciferase reporter gene activity, was determined by relative
luminescence after addition of substrate. ID50 values were defined as the sample
dilution required to reduce luminescence by 50% in comparison to wells with no
sample added.

Histopathology

Hematoxylin and eosin stained tissue slides were examined in a blinded
manner by a veterinary pathologist (M.P.) for gross or cellular abnormalities.

Pharmacokinetic Analysis

Pharmacokinetic Parameters were analyzed using PK Solutions Software
(Summit PK). Parameters were determined using GRFT serum concentrations at
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sampling time points. Values were generated from time vs. concentration
curves based upon amount of GRFT dosed/gram bodyweight. Values generated
included Absorption, distribution, and elimination half-lives, area under the curve
(AUC), volume of distribution (Vd), clearance, and maximum serum
concentration (Cmax).
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RESULTS

Pharmacokinetics-Intravenous Dosing
GRFT was detectible at all time points tested - including up to 96 hours
post dose (Figure 3.1). 15 minutes post intravenous administration, animals
displayed an average serum concentration of approximately 74 µg/ml and 141
µg/ml based on initial doses of 10 mg/kg and 20 mg/kg respectively. By 8 hours
after administration, serum concentrations had decreased to average
concentrations 897 ng/ml (10mg/kg dosage) and 1540 ng/ml (20 mg/kg dosage)
(Figure 3.1A). Analysis of elimination curves by Pk Solutions software revealed a
multiphasic elimination, with 3 distinct phases observed.

Early phase

elimination kinetics (0-2 hrs) revealed an absorption half-life of approximately 0.5
hours, with late phase elimination half-life ranging from 10 to 17 hours (Table
3.1). GRFT remained detectible in serum at low ng/ml concentrations up to 96
hours post intravenous treatment (Figure 3.1B).
Pharmacokinetics - Subcutaneous Dosing
After subcutaneous administration, GRFT displayed increasing serum
concentrations, reaching peak serum concentration approximately 4 hours post
subcutaneous administration (Figure 3.1A). Thereafter GRFT concentrations
decreased at rates analogous to those seen in intravenously dosed animals. At
10mg/ml, GRFT displayed a Cmax of 6.6 µg/ml whereas at 20 mg/ml GRFT
displayed a mean Cmax of 19.7 µg/ml. GRFT remained detectible in serum at low
ng/ml concentrations up to 96 hours post subcutaneous treatment.
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Pharmacokinetics - Oral Dosing
GRFT did not display any detectible serum concentrations at any time
point tested after oral administration.

Chronic GRFT oral treatment
Serum collected from rats orally dosed daily with PBS, 5 mg GRFT and
10mg GRFT did not display detectible GRFT concentrations on either day 5 or
day 10. Urine samples obtained from these rats also failed to display detectible
GRFT concentrations.

Fecal GRFT concentrations -Chronic Dosing
Fecal extracts from fresh fecal pellets displayed low concentrations of
GRFT. At 8 hours after initial dosing, animals treated with 5 mg and 10 mg
GRFT displayed an average fecal GRFT extract concentration of approximately 2
nM (Figure 3.2A). However, average GRFT concentration of both groups
decreased at 24hr after dosing, with fecal extracts from animals treated with 5mg
GRFT displaying an average concentration of 0.5 nM while animals treated with
10 mg GRFT displayed an average concentration of 0.75 nM. (Figure 3.2B).
Fecal extracts from random pellet draws also displayed varying amounts of
GRFT. Dessicated fecal pellet extracts drawn on days 2, 3, 8 and 9 were
analyzed. As expected, none of the fecal pellet extracts from PBS treated
animals displayed GRFT concentrations (Figure 3.2C). Fecal pellet extracts from
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animals treated with 5mg GRFT ranged from 1.7 nM to 20 nM. Fecal pellet
extracts from animals treated with 10 mg GRFT ranged from 1.7 nM to 126 nM.
HIV-1 Neutralization activity Fecal Pellect Extracts of Chronically treated animals.
Pooled fecal extracts from rats treated with 5mg and 10mg GRFT
neutralized HIV-1 pseudoviruses (Clade C primary sexually transmitted isolate
Du156) with an ID50 of 590 on experimental day 3 for those animals treated with
5mg GRFT and an ID50 of 2059 for animals treated with 10 mg GRFT (Figure
3.3). This neutralization activity was also observed in samples obtained at later
time points. On treatment day 8 sera from animals receiving a dosage of 5mg
GRFT had an ID50 of 885 while those receiving 10 mg had an ID50 of 9452 (Figure
3.3). On treatment day 9 fecal pellet extracts had ID50s of 2195 and 13307 for
groups receiving 5mg/kg and 10mg/kg GRFT respectively (Figure 3.3).
Mass Balance of Active GRFT
Active concentrations of GRFT were detected in urine or fecal material
produced during the first 24 hours following intravenous, subcutaneous and oral
dosage of 2.5 mg GRFT. After intravenous administration and subcutaneous
administration, GRFT was detected in urine (Figure 3.4). After intravenous
administration of 2.5 mg GRFT, approximately 131 µg of active GRFT was
recovered, whereas 41 µg of active GRFT was recovered from subcutaneously
treated animals. However, a different elimination profile was observed following
oral administration. Following oral administration, approximately 2.3 µg GRFT
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was recovered from fecal material. GRFT was not detectible in urine at any time
point tested in orally dosed animals.
Histology
Organ slides did not reveal any treatment-related pathologies. However
individual variation in slides attributable to sample preparation and sectioning
were observed.
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DISCUSSION
The pharmacokinetics data we derived here expand upon our previous
studies (Barton et al.), which showed that subcutaneous treatment with 10 mg/kg
GRFT was well tolerated in two laboratory rodent species (mice and guinea
pigs), and accumulated to therapeutically relevant levels – above GRFT’s antiHIV EC50 of 40 pM. Here we show in rats, a standard rodent model used for PK
studies, that GRFT has a complex PK profile which may prove important in
designing future studies.
As seen in Figure 3.1, GRFT displays different drug concentration curves
depending upon method of administration. Intravenously-dosed GRFT exhibits a
multiphasic elimination pattern, with the serum half-life changing over the
observation period. While the majority of a single dose of GRFT is eliminated
within 8 hours of treatment, potentially therapeutic concentrations above GRFT’s
anti-HIV-1 EC50 remain for at least 96 hours post administration. This complex
elimination pattern, which can vary among other protein based pharmaceuticals
in time to maximum serum concentrations and rates of elimination [193-195],
may represent multiple processes going on simultaneously. These may include
continual absorption, degradation, protein binding, and elimination processes.
GRFT was observed to be renally excreted in urine in substantial quantities
shortly after dosing intravenous dosing. However, this amount was also
observed to decrease over time. Further, prior research within our lab has
detected GRFT in vaginal mucous after subcutaneous dosing (observational
studies). Thus, it is possible that GRFT could still be distributing more
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extensively into deeper physiological compartments while other fractions of
GRFT are being eliminated. This speculation will require in vivo radiolabeling
studies of GRFT for a full determination as to GRFT’s ultimate fate. Further, it is
also possible that degradative proteolysis is occurring. While previous studies
have shown GRFT is relatively proteolytically resistant to many proteases, it has
been reported that GRFT is susceptible to leukocyte elastase [192]. Thus it is
possible that GRFT is vulnerable to some other unknown proteases as well. This
possibility will require both extensive in vitro protease degradation testing as well
as examination of degradation products in serum after systemic administration
using radiolabeled GRFT to determine whether GRFT is being degraded or
retained within the system.
The final phase of elimination of GRFT appears to be substantially longer
than the initial elimination phases. This persistence is comparable to other
protein therapeutics, such as monoclonal antibodies, which also present long
serum persistence[194] as well as smaller molecule biologics, such as
recombinant epoetin[193]—though recombinant epoetin concentrations have
been observed to be eliminated within two to three days after intravenous dosing
[188]. This serum persistence could potentially be from redistribution of GRFT
from deeper physiological compartments and mucosal surfaces. However, it is
also very possible, if not likely, that these low residual concentrations of GRFT
are interacting with or binding to endogenous proteins. To confirm this
possibility, in vivo testing with radiolabeled GRFT is suggested to identify if GRFT
is localizing to or redistributing from, a particular compartment. Additionally,
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cellular protein binding experiments may be useful to identify membrane bound
protein binding partners which may be responsible for GRFT’s long serum
persistence.
Subcutaneously dosed GRFT reaches peak serum concentrations at
approximately 4 hours post administration, with elimination patterns mirroring
intravenous dosage thereafter. The initial distribution phase immediately
following subcutaneously dosage appeared to be fairly comparable regardless of
amount of GRFT dosed. However, subcutaneous doses at higher drug
concentration increased GRFT’s peak concentration, total drug exposure and
bioavailability, as reflected in the area under the curve over the study period. It is
thought that the approximately 4 fold difference in total drug exposure observed
between 10 mg/kg and 20 mg/kg subcutaneous doses of GRFT could be
attributable to a gradual release or absorption of more GRFT from the site of
subcutaneous administration over the time course of treatment while competing
distributive, elimination, and degradative processes are occurring as it enters the
circulatory system from the capillary bed. Interestingly, it appears that the
concentration of GRFT dosed, and not necessarily the volume of the
subcutaneous bolus affected total drug exposure over the study period. A large
volume, lower concentration of GRFT tested did not have the sustained higher
serum concentrations (data not shown).
These pharmacokinetic results would seem to indicate that in a postexposure prophylactic setting, subcutaneous administration of GRFT may be a
viable method of administration. In the cases of Ebola virus and SARS-CoV, the
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viral latency period can range from 2 days or longer. In the context of HIV-1
exposure clinical settings, post-exposure prophylaxis initiated within 24-48 hours
of exposure has shown a protective effect [120]. Additionally, there are now
anecdotal evidence that even following seroconversion, immediate treatment with
anti-viral regimens can confer clinical benefits [196-198], and in the case of an
infant treated after birth, functional cure [199, 200]. Accordingly GRFT’s
observed pharmacokinetic profile, peak serum concentrations achieved 4 hours
post dosing, and persistence up to 96 hours post single treatment would suggest
the viability of daily subcutaneous self-dosage regimen to maintain potentially
therapeutic effect.
GRFT’s pharmacokinetic parameters will also be important in future
studies. Given that subcutaneous dosing may be a viable regimen to maintain
potentially therapeutic drug concentrations, the pharmacokinetic parameters of
GRFT may be useful in study design parameters such as: steady state drug
concentrations, loading doses, maintenance doses, and dosing intervals.
GRFT’s EC50 for HIV is approximately 40 pM [32]. From the clearance
parameters (0.06 L/hr) determined for 10mg/kg subcutaneous dosing, a 72 hour
dosing regimen of 2.5 mg GRFT would achieve a stead state concentration of 47
nM, over 1000 times higher than GRFT’s EC50 for HIV-1. However, GRFT’sHCV
EC50 has been described as 14 nM [31], whereas its SARS-CoV EC50 is
approximately 48 nM [23]. Accordingly, as GRFT is further studied in in vivo
animal models for varying viral diseases, it may be necessary to design dosing
intervals and concentrations necessary to maintain serum drug concentrations at
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potentially therapeutic steady state levels for that disease, while avoiding
concentrations that may induce toxicities. For example, with a calculated 14 hour
elimination-phase half-life seen in a 10 mg/kg subcutaneous dose and a 43%
bioavailability, a 72-hour dosing regimen would be necessary to minimize
bioaccumulation of GRFT. This data can also be utilized to design a more
frequent dosing regimen to minimize peak and trough concentrations of the drug
while maintaining a steady state serum concentration above concentrations
necessary for potentially therapeutic effect. For instance, to maintain a steady
state concentration of 47 nM, 35 µg/hr or 840 µg/day would need to be
administered. Alternatively, using these data, a loading dose followed by regular
maintenance dosing may be employed to achieve a desired steady state
concentrations above the EC50 for particular disease study model.
Interestingly, it also appears that the concentration of subcutaneously
dosed GRFT can affect its bioavailability. At 10mg/kg dosing, GRFT displayed a
43% bioavailability when subcutaneously dosed. Whereas at 20mg/kg dosing,
GRFT displayed a 90% bioavailablity (calculated as
AUC(subcutaneous)/AUC(intravenous) for each respective dose concentration).
The cause of this discrepancy is currently unclear and will require further study.
However, it highlights the impact that selection of dose concentration/kg may
have upon study design.
In contrast to subcutaneous and intravenous routes, orally administered
GRFT does not appear to be systemically absorbed. Other lectins, such as
wheat germ agglutinin, which bind to N-acetyl-D-glucosamine and sialic acid
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structures, have been used to increase systemic absorption of some other drugs
[201, 202]. However, given GRFT’s unique affinity for oligomannose glycans, it
was uncertain whether GRFT would have a similar utility. At no time point
examined was GRFT found in the serum of orally-treated animals. While this
difference in absorption and elimination profile likely makes GRFT unsuitable as
an orally dosed systemic therapeutic at this time, advances in drug delivery
systems for oral dosing of biologics may eventually enable an oral dosing method
for GRFT. However, GRFT’s current oral dosing profile raises the potential of
GRFT to be an orally-dosed, rectal microbicide for prevention of transmission of
HIV-1 and other sexually transmitted pathogens that GRFT is active against
(such as HSV-2). Non-absorption of GRFT via oral administration allowed for a
fraction of the drug to pass through the digestive tract, ultimately being expelled
in fecal waste (Figure 3.4). While this fraction is small, approximately 1% of the
initial dosage, methods to shield GRFT from further effects of stomach acids and
proteases could possibly be employed to make this fraction higher. Additionally,
as food was not controlled prior to oral administration of GRFT, food
consumption could potentially impact GRFT’s intestinal transit and successful
proteolytic survival. Nonetheless, as seen in both the single oral dose mass
balance as well as the chronic oral dosing, the concentration of GRFT in
prepared fecal extracts exceed GRFT’s EC50 versus HIV-1 over the first 24 hours
post treatment. Interestingly however, GRFT’s neutralization activity in fecal
extract did not correlate well with GRFT’s previously described EC50 of 40 pM,
though neutralization activity did correlate well with GRFT concentration. It is
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believed that this discrepancy may be attributable to the background
neutralization activity seen in fecal extracts from PBS treated animals.
Daily prophylactic treatment for HIV-1 is well established. For example, Truvada
is currently being prescribed to high risk populations, namely MSM to prevent
HIV infection [106, 203]. Additionally, anti-retrovirals are employed following
occupational and non-occupational exposure to prevent HIV infection [117-120,
204]. Thus, the observed fractional survival of active GRFT raises the potential
that GRFT could be utilized as a daily dosed treatment to “seed” the bowels and
rectal mucosa, where it could potentially block HIV infection through its
interaction with high mannose glycans on free virions.
Interestingly, the timing of passage of GRFT following oral dosage also
appears to be consistent with typical intestinal transit time of 20-30 hours. As
seen in Figure 3.2, some animals chronically treated GRFT began to excrete
GRFT in their fecal matter within 8 hours of initial treatment regardless of dosage
size. At 24 hours after treatment, more than half of the animals from each
treatment group were still excreting GRFT in their feces. With an intestinal transit
time of 8-24 hours, it would appear that the majority of GRFT administered is
passed between 8-20 hours of dosage in rats. However, it is currently unknown
what effect the co-administration of food would have upon GRFT’s transit time as
food was only restricted 20 minutes before administration. It is very possible that
intestinal transit time for GRFT would be increased if food were restricted before
administration.
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While enveloped viruses such as SARS-CoV, HIV-1, HSV-2 and HCV
continue to spread worldwide, it is imperative that all avenues for prevention be
evaluated to assess their overall population level effect. Our findings indicate
that GRFT’s pharmacokinetic profile supports multiple potential uses as well as
enables the design of different dosing regimens. As a systemic post-exposure
therapeutic or treatment, subcutaneous self-dosing would be both a viable and
effective means to achieve potentially therapeutic serum concentrations of
GRFT. In the context of post-exposure prophylaxis to emerging viral threats, an
initial intravenous bolus treatment may be useful to achieve very rapid peak
serum levels of GRFT (Figure 3.1.) Further, given the apparent non-absorption of
GRFT following oral administration, as well as the continued anti-viral activity of
GRFT found in fecal materials, it is possible that GRFT could be utilized as an
orally dosed rectal microbicide in a pre-exposure prophylactic setting. While
admittedly, it is only a small fraction of GRFT dosage which survives intestinal
transit, we have demonstrated that levels above its anti-HIV EC50 are achievable.
Nonetheless, methods may be needed to shield GRFT from excessive
degradation or inactivation.
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Figure 3.1. Pharmacokinetic profile of GRFT in Serum. Mean GRFT
concentrations present after single Intravenous (IV) and Subcutaneous (SQ)
dose (n=3-4 per group) (A). Serum Concentrations from animals dosed with 10
mg/kg GRFT both 72 and 96 hours after administration (B). Bars indicate mean
± standard deviation of 5 biological replicates
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INTRAVENOUS

SUBCUTANEOUS

Units

10 mg/kg
(N=4)

20 mg/kg
(n=3)

10 mg/kg
(n=4)

20 mg/kg (n=4)

INITIAL
DISTRIBUTION
HALF LIFE
(0.25-2 HR)

hr

0.51 ± 0.09

0.46 ± 0.18

--

--

ABSORPTION
HALF LIFE
(0.25-2 HR)

hr

--

--

1.3 ± 0.3

1.6 ± 0.4

DISTRIBUTION
HALF LIFE
(4-8 HR)

hr

1.7 ± 0.3

2.1 ± 0.7

2.1 ± 0.9

2.8 ± 1.2

ELIMINATION
HALF LIFE
(24-48 HR)

hr

10.7 ± 4.6

17.5 ± 6.1

13.8 ± 6.8

6.6 ± 1.9

mg-hr/L

110 ± 20

200 ± 30

50 ± 10

180 ± 50

L

0.35 ± 0.13

0.57 ± 0.15

1.2 ± 0.6

0.23 ± 0.10

L/hr

0.026 ± 0.006

0.023 ± 0.004

0.058 ± 0.008

0.024 ± 0.006

µg/ml

80 ± 30

180 ± 30

6.6 ± 0.6

20 ± 2

AUC

VD

CLEARANCE

CMAX

Table 3.1. Pharmacokinetic parameters of GRFT over 48 hours. Data represent
the mean values +/- standard deviation for initial distribution (intravenous),
absorption (subcutaneous), distribution, and elimination half-lives, area under the
curve (AUC), volume of distribution (VD), clearance, and maximum serum
concentration (Cmax).
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Figure 3.2. GRFT Concentrations in Fecal Extracts following Chronic Oral
dosing. Mean GRFT concentrations from fecal extracts prepared from fresh fecal
pellets obtained 8 hours (A) and 24 hours (B) after oral dosage with either PBS, 5
mg GRFT, or 10 mg GRFT. Bars indicate mean ± standard deviation of 5
biological replicates. Mean GRFT concentrations of fecal extracts prepared from
desiccated pellets randomly drawn from cages (two animals per cage) on select
days (C). Bars indicate mean ± standard deviation of 3 biological (cage)
replicates.
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Figure 3.3. Antiviral activity of pooled fecal extracts collected on select days
during the course of chronic oral treatment with GRFT. HIV-1 env- pseudovirus
neutralization activity (EC50 of GRFT = ~40 pM) was assessed for pooled rat fecal
extracts from animals dosed with either PBS, 5 mg or 10mg GRFT and
expressed as ID50 (dilution factor required to reduce luminescence to 50% of
PBS treated controls) (A). The mean GRFT concentrations were determined and
compared to interpolated ID50 values (B).
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Figure 3.4. Total GRFT recovery following single administration. Based upon
likely route of excretion, urine or fecal samples were obtained for animals
receiving 10 mg/kg GRFT after Intravenous (IV), Subcutaneous (SQ), and oral
administration. GRFT concentrations in urine and fecal extracts were determined
and mean GRFT recovered was calculated. Bars indicate mean ± standard
deviation of 5 biological replicates.
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CHAPTER 4
SUB-CHRONIC SUBCUTANEOUS TREATMENT WITH THE ANTIVIRAL
LECTIN GRIFFITHSIN IN RATS TO DETERMINE GRIFFITHSIN’S SYSTEMIC
TOLERABILITY AND EXAMINE GRIFFITHSIN’S EFFECTS UPON ORGANS,
BLOOD CELL COUNTS, SERUM CHEMISTRIES, AND CYTOKINE
PRODUCTION
INTRODUCTION
The oligomannose glycan structures displayed on the surface of many
human and animal pathogenic viruses are potential targets for antiviral
therapeutics. CBAsact by targeting and binding to viral oligomannose glycans
and include both lectin and non-peptidic drugs [14, 205]. CBA relevance in viral
therapy stems from the fact that, among enveloped viruses, glycans shields can
be used for cellular entry, immune evasion, and in some cases, innate immune
response suppression[13, 17, 19, 51, 60]. In vitro antiviral activity of CBAs
against a broad array of enveloped viruses has been observed and verified by
others [28, 29, 189]. However, most carbohydrate binding agents that display
broad spectrum, strongly inhibitory antiviral activity are lectins that present
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several theoretical safety concerns for development as biologic therapies[14, 22,
24, 149]. Chief amongst the safety concerns are toxicities associated with offtarget activity, and immunotoxicities including hypersensitivity and production of
anti-drug antibodies (ADA) that might neutralize the lectin antiviral activity and
lead to undesirable side effects over long-term therapy.
One of the most promising antiviral lectins is the red alga Griffithsiaderived homodimeric lectin Griffithsin. GRFT (12.77 kDa) is a lectin that binds
terminal mannose residues on (N)-linked Man5-9GlcNAc2 structures on viral
envelopes [32, 163, 165]. These oligomannose glycans comprise the vast
majority of N-linked glycans in the HIV-1 glycan shield [13, 16]. Consequently,
GRFT has exceptional activity—in the mid picomolar range—against the heavily
glycosylated lentiviruses HIV-1 and HIV-2[32, 33], and nanomolar inhibitory
activity against other viruses of public health importance, such as HCV [30, 31],
JEV [173] as well as SARS-CoV in addition to other CoV pathogens [23]. Data
published by our group and others show that GRFT does not induce
inflammatory cytokines on treatment of cultured human cells and primary
lymphocytes; does not agglutinate human red blood cells; shows an excellent
safety profile in highly sensitive preclinical safety models designed to predict
toxicity at vaginal epithelia; and shows minimal toxicity after short-term oral,
subcutaneous and intravenous exposure. Much like the in vivo studies into the
efficacy of CBAs as antiviral treatments to inhibit influenza and Ebola viruses [28,
29], in vivo and ex vivo studies using GRFT in multiple murine virus challenge
models have also shown promise. For example, intranasally administered GRFT
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prevents disease in mice challenged with SARS-CoV [172]. Intraperitoneal (IP)
treatment with GRFT has prevented JEV [173]. Furthermore, GRFT showed
efficacy against HCV in a mouse-human chimeric liver model when administered
subcutaneously [30, 170].
Our previous studies have shown that an acute subcutaneous treatment of
GRFT in guinea pigs and mice for a period of ten (10) days was tolerable with
minimal toxicity reported [34]. We also showed that subcutaneous administration
of GRFT at 10 mg/kg remains at potentially therapeutic concentrations up to 48
hours after administration, with therapeutically-relevant concentrations persisting
for over a week after a single 50 mg/kg administration in mice [34]. However, as
a xenogeneic protein, GRFT has the potential to elicit an immune response, up to
and including anaphylaxis. Accordingly, longer term administration studies are
necessary to assess GRFT’s potential as a systemic therapeutic. Furthermore,
the impact that ADA may have on GRFT’s pharmacological activity,
pharmacokinetics, and in vivo toxicity profile is unknown.
Here we report that minimal toxicity is induced by subcutaneous doses of
GRFT in rats after approximately 8 weeks of treatment, though development of
immune responses that may cause IgG ADA may require more prolonged and
periodic monitoring. The drug remained systemically distributed, and
accumulated at physiologically relevant levels after subcutaneous delivery for all
time points tested. Inflammatory cytokine analysis at treatment cessation did not
reveal widespread alterations in inflammatory cytokine levels, though some
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significant changes were observed in macrophage inflammatory proteins and
leptin levels. Importantly we demonstrated that serum from GRFT treated
animals retained anti-viral activity against HIV-1 envelope pseudoviruses in a cell
line-based neutralization assay despite a modest ADA response to the GRFT.
Overall, these findings support further investigation into GRFT’s potential as a
systemic antiviral therapeutic agent against enveloped viruses including HIV-1.
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MATERIALS AND METHODS
Lectin reagents
Recombinant GRFT was produced as described previously, purified to
>99% purity, and formulated in phosphate buffered saline (PBS), pH 7.4 [169].
Animal housing and care
225-250g Sprague Dawley Rats (Rattus Norvegicus, Charles River
Laboratories), housed in a temperature- and humidity-controlled room with an
alternating light/dark cycle of 12h, were provided a standard diet and water ad
libitum. All experimental procedures utilized were approved by the University of
Louisville’s Institutional Animal Care and Use Committee.
Rat IgG Generation
To generate IgG antibodies for passive immunization, 9 Sprague Dawley
rats (250g+) were injected subcutaneously with 500 µl Sigma Adjuvant
(monophosphoryl lipid A, synthetic trehalose dicorynomycolate in 2% squaleneTween® 80-water) and GRFT formulated at 1mg/ml per manufacturer’s
recommended protocol. Booster immunizations were performed according to
manufacturer protocol every 3 weeks for 12 weeks. Two weeks after final
immunization animals were sacrificed by CO2 asphyxiation and serum was
collected via cardiac puncture. Ig from these samples was purified by NAB spin
column (Sigma) according to the manufacturer’s protocol. For nonspecific
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controls, IgG from commercial Sprague Dawley rat serum (InnovoResearch) was
purified by NAB spin column (Sigma). Ig was then dialyzed (Thermo 3500
mwco) against PBS to remove elution buffer and sterile filtered prior to
subcutaneous administration.
Rat treatment and sample collection
Age-matched, 225g Sprague Dawley rats were allowed to a week to
acclimate before treatment according to the treatment regimen diagram shown in
Figure 4.1. After acclimation, two groups were pre-immunized with either 0.5 ml
of Sigma Adjuvant and GRFT at 1mg/ml (n=7) or 0.5 ml Sigma Adjuvant and PBS
(n=6) before commencing treatment. Pre-immunized animals were boosted
twice at three week intervals. Animals not undergoing pre-immunization were left
fallow during the pre-immunization phase. Treatment groups consisted of the
following: pre-immunized with Adjuvant and PBS (n=6), pre-immunized with
GRFT and Adjuvant (n=7), GRFT treated (n=7), PBS treated (n=6), GRFT treated
and passively immunized with anti-GRFT Ig (n=7), PBS treated and passively
immunized with nonspecific Ig (n=6). Animals were treated subcutaneously with
either PBS or 10mg/kg GRFT every three days. Passively-immunized animals
also received 1.4 mg of appropriate Ig formulated in 1 ml of PBS every 14 days.
Serum was drawn via lateral tail vein on the following days: Day 10, 24,
38, and 52. Animals were sacrificed on day 55 via CO2 asphyxiation followed by
cardiac puncture exsanguination. Blood, hearts, lungs, kidneys, liver, spleen,
colon, and vaginas were collected at sacrifice for analysis.
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GRFT capture immunoassay using the HA glycoprotein.
To detect active concentrations of GRFT present in serum we used an
Influenza HA binding ELISA. Briefly, Maxisorp plates (Nunc) were coated with 10
µg purified HA (Kentucky Bioprocessing) and incubated overnight at 4 oC. Plates
were blocked with ~3% (w/v) Bovine Serum Albumin (BSA) in PBS-T. Serum
samples were diluted 1:10 in blocking buffer. Serial dilutions of purified GRFT
were run in parallel for generation of a standard curve. Serum and GRFT
dilutions and were incubated at RT for 1 hour. HA-bound GRFT was detected by
rabbit anti-GRFT antiserum (1:25,000) followed by HRP-conjugated goat antirabbit IgG (1:10,000). Plates were developed with SureBlue TMB Microwell
Peroxidase Substrate, with reactions stopped with 1N H2SO4 after 10 minutes of
development. Absorbance readings at 450 nm and 570 nm wavelengths were
measured using a BioTek Synergy HT plate reader. Concentrations were
determined by Nanoanalyze software.
Evaluation of Anti-HIV Activity.
HIV-1 neutralization activity of heat-inactivated serum samples obtained
on day 52 and 55 was measured using pseudovirus neutralization assays as
previously described [174]. Briefly, DU156 env-pseudotyped virus particles
generated by transfection of 293T cells were titrated in TZM-bl cells both in the
presence and absence of serum sample dilutions. Antiviral activity of the serum
samples was calculated as a function of luciferase activity. ID50 values were
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defined as the sample dilution required to reduce well luminescence by 50% in
comparison to wells with no sample added.
Hematology parameters and Serum Chemistry.
A complete blood count (CBC) was run for terminal bleed samples using a
Hemavet® 950 (Drew Scientific) standardized for rat blood. Parameters
quantified in potassium-EDTA anti-coagulated whole blood included: red blood
cells (RBC; 104/µl), total and differential leukocyte count (neutrophils,
lymphocytes, monocytes, eosinophils, and basophils as 103/µl or %), hemoglobin
concentration (HGB; g/dl), hematocrit (HCT; %), mean corpuscular volume (MCV;
fl), mean cell hemoglobin (MCH; pg), mean cell hemoglobin concentration
(MCHC; g/dl), red cell distribution width (RDW; %), platelets (PLT; 104/µl), and
mean platelet volume (MPV; fl).
Serum chemistry panels were also run for terminal bleed samples using a
VetTest® Chemistry Analyzer (IDEXX Laboratories). Parameters quantified from
serum included: serum albumin (Alb), alkaline phosphatase (ALKP), amylase
(Amy), alanine aminotransferase (ALT), blood urea nitrogen (BUN), calcium (Ca),
cholesterol (Chol), creatinine (Creat), globulin (Glob), glucose (Glu), phosphorus
(Phos), total bilirubin (TBil), and total protein (TP).
Rat Antibody titration
To quantitate degree of immune response to GRFT, antibody titers were
determined for terminal bleed samples (day 55) using a sandwich ELISA. Briefly,
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Maxisorp plates (Nunc) were coated with 5 ug purified HA (Kentucky
Bioprocessing) and incubated overnight at 4C. Plates were blocked with ~3%
(w/v) Bovine Serum Albumin (BSA) in PBS-T. 10ug/ml GRFT (to excess) was
diluted in blocking buffer and incubated at RT for 1 hour. Serial dilutions of
sample sera diluted in PBS-T containing 2M urea were incubated in wells for 2
hours. GRFT-bound rat Ig was detected by HRP-conjugated Donkey anti-rat
polyclonal antibody (1:25,000). Plates were developed with SureBlue TMB
Microwell Peroxidase Substrate, with reactions stopped with 1N H2SO4 after 10
minutes of development. Absorbance readings at 450 nm and 570 nm
wavelengths were measured using a BioTek Synergy HT plate reader. Final
absorbance 2 times background was considered a positive signal for a particular
dilution.
Cytokine Quantitation
To measure any inflammatory effects of chronic exposure, cytokine levels
in samples drawn on day 52 were determined by Milliplex Map Kit (Millipore)
using manufacturer’s standard protocol. The following cytokine levels were
quantified: granulocyte colony-stimulating factor (G-CSF), Eotaxin, Granulocyte
macrophage colony-stimulating factor (GM-SCF), Interleukin 1 alpha (IL-1a),
Leptin, Macrophage Inflammatory Protein 1 alpha (MIP 1-a), Interleukin 4 (IL4),
Interleukin 1 beta (IL-1B), Interleukin two (IL-2), EGF, Interleukin 13 (IL-13),
Interleukin 10 (IL-10), Interluekin 12 (IL-12p70), Interferon gamma (INFy),
Interleukin 5 (IL-5), Interleukin 17 alpha (IL-17A), Interleukin 18 (IL-18),
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monocyte chemoattractant protein 1 (MCP-1), interferon gamma induced protein
10 (IP-10), growth-related oncogene (GRO/KC), vascular endothelial growth
factor (VEGF), Fractalkine, lipopolysaccharide induced CXC chemokine (LIX),
macrophage inflammatory protein 2 (MIP-2), tumor necrosis factor alpha (TNFa),
and Rantes.
Statistical Analysis.
Statistical analysis was conducted using Graph Pad Prism 5. Two-way
ANOVA was utilized. A p-value < 0.05 was deemed significant. Bonferonni posttests were conducted to determine whether any differences were attributable to
GRFT treatment.
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RESULTS
GRFT serum concentrations.
Serum samples collected from all rats treated with 10mg/kg GRFT showed
nanomolar concentrations of GRFT at every time point tested (Figure 4.2A).
These levels predictably varied by time since last dosage, which ranged from 24
to 72 hours after administration. In Day 52 sera (24 hours after final
administration), all groups treated with GRFT displayed active mean GRFT
concentrations of approximately 10 nM. Notably, these concentrations of GRFT
persisted at mean levels of approximately 4 nM, regardless of GRFT treatment
subgroup, at 96 hours after dosing. Serum concentrations from GRFT treated
animals were also compared to serum concentrations from prior single
subcutaneous administration studies described in Chapter 3 (Figure 4.2B). Mean
GRFT concentrations in animals chronically treated with GRFT were higher at all
time points versus serum concentrations from animals receiving a single dose.
Anti-GRFT and Anti-HIV Activity of serum.
Serum Samples displayed varying levels of Anti-GRFT activity based upon
treatment group (Figure 4.3A). GRFT treated animals (without pre-immunization)
showed GRFT titers slightly elevated over background. Animals receiving
passive Ig immunization and pre-immunization with GRFT and adjuvant had the
highest mean activity titrations at 1:767 and 1:1542 respectively. There was clear
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variability in the GRFT antibody titers in both the pre-immunized and passively
immunized groups.
Serum samples collected from rats treated with 10 mg/kg GRFT
neutralized HIV-1 pseudoviruses (Clade C primary sexually transmitted isolate
Du156) with an overall mean ID50 of approximately 20500 on experimental day
52 (Figure 4.3B). The antiviral activity measured in rat sera was not statistically
different between animals that were immunologically naïve at the study outset
(GRFT group) versus the preimmune group and the passively immunized group.
After a 96 hour recovery period, group mean ID50 values decreased to
approximately 4300 on day 55. PBS treated rat sera displayed a mean ID50s of
264 and 112 on days 52 and 55, respectively. Both pre-immunized and passively
immunized groups also receiving GRFT treatment displayed strong neutralization
activity on Day 52 as well, with mean ID50 values of 19800 and 17000
respectively. These group mean ID50s also decreased 96 hours after treatment,
similarly to animals treated only with GRFT. Rat neutralization titers did not
correlate well with GRFT’s published anti-HIV-1 EC50 of 40 pM, likely as a
product of background neutralization activity observed in rat serum.
GRFT is well tolerated after chronic subcutaneous administration
We studied the toxicity of GRFT in rats using several parameters including
mortality, behavior, animal body and organ weight changes, tissue pathology, and
changes in blood properties.
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All animals survived treatment with no behavioral changes observed.
Body weight, as a surrogate marker for overall fitness following GRFT treatment,
was evaluated. Animals were weighed at day 1 and day 55. Using a 2-way
ANOVA, we found no significant changes in starting weight or weight gain among
treatment groups (p=0.4177 and p=0.9170 respectively, Figure 4.4).
Liver, kidney, and spleen weights were measured at sacrifice and
normalized to total body weights. No significant changes of the normalized
weights of livers were observed (p= 0.1487, Figure 4.4C) However, animals
passively immunized with GRFT IgG and treated with GRFT displayed
significantly lower kidney/body weight ratios in comparison to PBS treated
controls (p=0.0328, Figure 4.4D). Additionally, we observed a trend toward larger
spleen weights in all animals treated with GRFT, regardless of whether they were
pre-immunized (p=0.0561, Figure 4.4E).
Tissue sections were stained with hematoxylin and eosin and evaluated in
a blinded fashion by a veterinary pathologist (MaryProctor). The pathologist
noted differences among individual animals that were attributable to sample
preparation and sectioning. However, no treatment-related pathologies were
observed for any treatment group.
CBC results displayed no significant changes among groups though Red
Blood Cell Width and Platelet values approached significance with p-values of
0.0977 and 0.0796 respectively (Table 4.1). Serum chemistries displayed some
statistically significant differences among treatment groups (Table 4.2). Among
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these were albumin, amylase, phosphorus, blood urea nitrogen, and globulin.
Bonferroni post-test identified differences among treatment groups. Phosphorus
levels were significantly higher in vehicle-only (PBS) than in all GRFT treated
groups (p=0.0083). Amylase and globulin levels were significantly higher in
Passively Immunized/GRFT treated animals though amylase levels were within
the normal range for rats (p=0.0468 and p=0.002 respectively). Finally, albumin
levels were significantly lower in pre-immunized/GRFT treated animals than in
PBS treated controls, though within the normal range for rats (p=0.0071).
Cytokine responses
Cytokine panels with a minimum of 3 positive signals per group were
analyzed. Analysis of PBS, GRFT, Pre-Imm/GRFT, and Pass-Imm/GRFT
revealed only 4 significant differences among the cytokines examined: Leptin,
MIP-1a, Ip-10, and MIP-2 (Table 3). In the case of leptin, all groups treated with
GRFT had significantly lower leptin levels than PBS treated controls (p=<0.0001).
Further, IP-10 levels were lower in the group receiving GRFT-only treatment
(p=0.0312). MIP-1a elevation was seen in the pre-immunized/GRFT treated
group (p=0.018). However, posttest analysis did not reveal significance versus
PBS-treated controls, but rather significance versus GRFT-only treated animals.
Finally, MIP-2 displayed a significant difference among treatment groups
(p=0.0382). However, post-test analysis failed to identify differences between
individual groups.
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DISCUSSION
In this study, we demonstrate that intermediate term sub-chronic GRFT
administration is tolerated in rats, despite high levels of experimentally induced
ADA. Levels of ADA varied among groups and also varied widely within groups.
High anti-GRFT antibody titers were not observed in any animal even when preimmunized with adjuvant. Regardless of ADA levels, GRFT persisted in serum at
concentrations above the EC50 described for multiple enveloped viruses [23, 31,
32, 178]. Further these levels were observed in all GRFT treated animals, at all
time points tested, and up to 96 hours after administration. Although predictably
decreasing after final administration, functionally active GRFT concentrations--as
determined by HA binding ELISA and HIV-env pseudovirus neutralization assay-remain in circulation for many days after treatment cessation. These findings
support the continued study of GRFT as a viral therapeutic.
As noted in prior studies, a favorable safety profile for a drug must be
demonstrated to advocate for its further development [34, 35]. We observed
previously that GRFT was capable of persisting in the system for many days after
administration at potentially therapeutic levels when subcutaneously or
intravenously dosed ([34] and manuscript in preparation). Thus greater time
between administrations was selected to mimic a more favorable dosing regimen
that would be more acceptable for those relying upon subcutaneous selfadministration while not allowing GRFT to completely clear systemic circulation.
Based upon prior work, which described GRFT’s clearance in rats following
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subcutaneous administration at 10mg/kg at 0.058 L/hr, a dosing regimen of 2.5
mg every 72 hours was calculated to generate steady state concentrations of
GRFT of 47 nM, over 1000 times GRFT’s anti HIV-1 EC50 of 40 pM. Further,
this extended dosing regimen was sufficient to keep GRFT in the system at
concentrations well above its EC50 for HIV at 96 hours after final dose, thus
suggesting longer potential periods between administrations in humans may also
be possible, if not ideal. Injection administration of antiviral therapies is not
unheard of, and research is currently being conducted into long acting anti-viral
medications for HIV prevention and treatment [206-208]. Accordingly, efforts to
prolong GRFT’s serum persistence may be necessary to further enhance an
already acceptable administration profile.
In these current in vivo studies in rats, GRFT was not observed to alter
experimental animal behavior, nor did any animal die as a result of treatment.
Potential organ toxicity was also assessed by visual inspection during necropsy,
weight measurements and histopathology. No differences in organ appearances
were observed during necropsy. While kidney weight percentages of total body
weight in passively immunized/GRFT treated animals displayed a statistically
significant lower percentage in comparison with PBS-treated controls and preimmunized/GRFT treated animals trending toward lower percentages as well,
histopathological examination of the organs did not show any treatment-related
pathologies. Given the animals in this study were still growing, these lower
percentages may be a result of either impaired kidney growth or potential
nephrotoxicity. A prior study (manuscript currently in preparation) showed a
90

significant excretion of active GRFT into urine after both intravenous and
subcutaneous systemic administration. Accordingly, given that the observed
changes in kidney weights were seen in animals in which had significantly higher
globulin levels, it is possible that GRFT-antibody complexes or some component
on an immune response have an impact upon the renal function. Further
supporting this possibility was the observed trend toward lower kidney weight
and higher globulin levels also observed in pre-immunized/GRFT treated
animals. Accordingly, further study will be necessary to determine how an
antibody response impacts kidney function given that no histopathological
abnormalities were observed by the veterinary pathologist (M.P.).
When a complete blood count was performed and serum chemistries
analyzed, we observed that no CBC parameters were significantly changed as a
result of GRFT treatment. However, serum chemistries did show some variation.
Post hoc analysis revealed that amylase and globulin levels were significantly
higher in passively-immunized/GRFT treated animals versus PBS treated
controls. While amylase levels were still within the normal range for rats, elevated
globulin levels could reasonably be expected as an outcome of Ig administration,
and thus could be a confounding effect derived from the experimental treatment.
Significant differences in albumin and BUN in pre-immunized animals
versus PBS treated controls were observed. Interestingly, the difference in BUN
combined with the trend toward a lower kidney to bodyweight ratio may suggest
a degree of kidney impairment associated with an immune response to GRFT
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which impairs kidney excretion of urea, as elevated BUN levels can be indicative
of kidney malfunction [209, 210]. Finally, a difference in phosphate levels was
observed in PBS treated animals in comparison with all GRFT treated groups.
However, closer analysis revealed that the PBS group average may have been
skewed by two high values and all values for phosphate were within the
physiological normal range for rats.
While prior studies have demonstrated that GRFT is not mitogenic, is not
cytotoxic to cells, and does not induce cell mediators of inflammation [35], a
major concern with an immune response to GRFT is that, as a xenogenic protein,
anaphylaxis is possible [180]. Although GRFT is a relatively weak immunogen,
we were able to raise a modest IgG antibody response in animals pre-immunized
with GRFT in the presence of adjuvant. Fortunately, it appears based upon both
ELISA and pseudovirus neutralization assay that immune sera are binding, but
non-neutralizing.
Immunogenicity of biologic drugs such as GRFT is a known issue and in
this study we demonstrate that while tolerable, some physiological changes may
be induced by an IgG based immune reaction to GRFT. Despite differing IgG
models of an immune response, it appears that GRFT administration does not
significantly impact the majority of cytokines examined. This corroborates prior
studies suggesting that GRFT does not induce cell mediators of inflammation
[35]. Nonetheless, there were some notable exceptions. The most significant
difference observed was in leptin levels. Leptin is a hormone made by body fat
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to regulate food intake and body weight. However, it has also been implicated in
T-cell regulation as well as inflammation, wherein leptin is considered proinflammatory and proangiogenic [211]. These findings of decreased leptin levels
in all GRFT treated groups may indicate some anti-inflammatory effect of GRFT
treatment. However, further studies into GRFT’s interactions with leptin are
needed to determine the exact mechanism by which leptin levels are lowered,
though interestingly, a lower body weight gain was observed in guinea pigs
treated with GRFT in a previous study [34]. This same conclusion may be drawn
from IP-10 levels. IP-10 (interferon inducible protein-10) levels were significantly
lower in animals receiving GRFT treatment in absence of pre-immunization or
simulated immune response. Thus, in animals in which no immune response
was generated or simulated, IP-10 levels were seen to decrease, further
supporting the possibility that GRFT may have some discrete anti-inflammatory
activity. However, once an immune response was initiated, it seems this effect
may disappear. MIP-1a and MIP-2 were elevated in animals pre-immunized with
GRFT and adjuvant. In the case of MIP-1a, the elevation was significant in preimmunized/GRFT treated animals versus PBS treated controls. In the case of
MIP-2, ANOVA post hoc analysis did not reveal the source of the variation.
However, both GRFT and GRFT/passively immunized animals displayed
decreased levels of MIP-2 verses PBS controls, while the pre-immunized GRFT
treated group was elevated versus PBS controls. While further study into the
exact effect of GRFT on these cytokines will be necessary, these results seem to
suggest that GRFT may function to slightly decrease inflammation. These results
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also raise the possibility that GRFT may have an immunosuppressive effect.
Further immune suppression would likely be undesirable in HIV disease and may
present a barrier to usage in those with existing infections. Additionally, the
specter of immunosuppression may require additional testing, such as viral,
bacterial, and tumor infection challenges as well as a full complement of in vitro
cell activation assays to ensure that GRFT does not prevent humoral or adaptive
immune response to other pathogens.
Resistance to CBAs occurring through a loss of specific N-linked
glycosylation sites has been observed when those viruses are placed under drug
pressure with CBAs [25, 185-188]. In HIV-1, CBA resistance has been correlated
with reduced viral fitness leading to a potentially enhanced susceptibility to
endogenous antibody neutralization [14, 186, 188]. Thus it has been
hypothesized by Balzarini and others that CBA therapy may induce resistance to
the CBA while enhancing susceptibility to immune system neutralization,
particularly in the case of HIV-1[14]. GRFT’s continued antiviral activity even in
presence of an immune response, as well its ~8 week tolerability profile, would
seem to indicate that GRFT is a candidate drug to test that hypothesis, as it
could be used for longer intermittent periods in attempts to guide viral resistance
evolution.
These results demonstrate that despite both pre-immunization and
passive immunization, no animal mortality was observed in any treated animal.
Furthermore, unlike our prior studies in guinea pigs and mice, our current data
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does not show significant treatment-associated increases in spleen and liver
mass-to-bodyweight ratios, though spleen differences approached significance,
probably associated with an immune response to GRFT. However, it does
appear that an immune response may result in kidney involvement, the exact
nature of which is not clear at present. As such, future efforts to de-immunize
GRFT may be necessary [161, 162], before it is viable as a long-term chronic
treatment of viral infection in humans. Nonetheless, we conclude that the
preliminary toxicity profile of GRFT is acceptable and encourages its further
development as an intermediate term antiviral prophylaxis and therapy.
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Figure 4.1. Treatment Regimen to evaluate the impact of an immune response
upon GRFT’s systemic tolerance and activity. Animals were separated into
groups of 6-7 animals and dosed every 3 days with either PBS or GRFT during
course of treatment. Select groups were pre-immunized prior to treatment
commencement (3 and 5) or passively immunized with IgG during chronic
treatment (4 and 6).
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Figure 4.2. GRFT serum concentrations in rats during and after chronic GRFT
treatment and comparisons with single dose pharmacokinetic values. (A) GRFT
concentrations were determined (12.77 kDA) from rat sera of naïve, preimmunized (pre-imm), or passively immunized (passive-imm) animals following
chronic PBS or 10mg/kg GRFT administration on day 10 (24 hrs after dosage),
day 24 (72 hours after dosage), day 38 (48 hours after dosage), day 52 (24 hours
after dosage), and day 55 (96 hours after dosage). PBS was administered to
control animals Error bars indicate standard deviation of 7 biological replicates.
(B) Mean GRFT concentrations of chronic dosing and a single subcutaneous
dose (projected using Clearance value of 0.058L/hr) reflect minor GRFT
accumulation during treatment.
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Figure 4.3. Titers of anti-GRFT IgG and antiviral activity of sera from rats preimmunized against GRFT, passively immunized with GRFT IgG, and controls.
Anti-GRFT activity of Rat serum at Day 55 was evaluated via titration (A). HIV-1
env-pseudovirus neutralization activity was assessed for rat sera 24 hours after
final administration of GRFT (Day 52) and 96 hours after final administration (Day
55) (B). Antiviral activity was expressed as ID50. Control animals were treated
with PBS. Anti-HIV-1 EC50 of GRFT = ~40 pM. Bars indicate mean group
concentration.
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Figure 4.4. Starting weight, weight gain over treatment, and Organ percentages
from rats preimmunized against GRFT, passively immunized with GRFT IgG, and
controls. Animal bodyweights were measured on experimental day 1 (A) and at
termination. Weight gain over treatment was calculated for each animal (B).
Liver (C), Kidney (D) and Spleen (E) weights were measured relative to body
weight at sacrifice. Bars indicate group mean and standard deviation of 6 to 7
biological replicates. Significant (p<0.05, One way ANOVA with Bonferroni
posttest) is indicated by (*).
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Cell Type
Leukocyte

Erythrocyte

GRFT
(n=7)
8.98±2.80

Pre-Imm /
GRFT
(n=7)
10.53±3.90

Pass-Imm /
GRFT
(n=6)
8.75±4.82

Pvalue
0.5978

Parameter
WBC

Units
K/µL

PBS
(n=6)
7.86±2.22

Ne

K/µL

2.63±0.60

3.05±1.16

3.66±1.30

2.77±1.50

0.4281

Ly

K/µL

4.62±1.59

5.35±1.60

6.04±2.45

5.37±3.02

0.7317

Mo

K/µL

0.37±0.21

0.41±0.24

0.62±0.32

0.38±0.33

0.3267

Eo

K/µL

0.19±0.10

0.14±0.13

0.16±0.18

0.16±0.10

0.9540

Ba

K/µL

0.05±0.04

0.03±0.05

0.04±0.04

0.05±0.02

0.9269

RBC

M/µL

6.63±0.51

6.33±0.79

6.55±0.54

6.07±1.39

0.6663

Hb

g/dL

14.0±0.6

13.7±0.7

13.4±1.3

12.5±2.3

0.2428

HCT

%

37.0±1.9

34.2±4.8

35.2±2.8

32.7±8.0

0.4891

MCV

fL

55.9±2.8

54.0±2.8

53.7±1.1

53.7±1.4

0.2442

MCH

pg

21.2±1.0

21.9±3.4

20.4±0.9

20.8±1.6

0.5537

MCHC

g/dL

37.9±1.4

40.8±7.4

38.0±1.6

38.7±4.1

0.6119

RDW

%

14.0±0.5

13.8±0.6

14.4±0.4

14.4±0.4

0.0977

Plt

K/µL

859±314

890±325

655±185

542±184

0.0796

MPV

fL

7.5±0.4

7.6±0.3

7.5±0.4

7.7±0.4

0.7263

Thrombocyte

Table 4.1. Hematological profile for rats after chronic treatment with GRFT.
Data represent the mean values +/- standard deviation for white blood cells
(WBC), neutrophils (NE), lymphocytes (LY), monocytes (MO), eosinophils (EO),
basophils (BA) , red blood cells (RBC), hemoglobin (Hb), hematocrit (HCT),
mean corpuscular volume (MCV), mean cell hemoglobin (MCH), mean cell
hemoglobin concentration (MCHC), red cell distribution width (RDW), platelets
(PLT), and mean platelet volume (MPV). Significance (p<0.05, ANOVA) is
indicated by (*).
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ALB

UNITS
g/dL

NORMAL
RANGE
3.8-4.8

PBS
(N=6)
5.1±0.9

GRFT
(N=7)
5.0±0.3

PRE-IMM
/GRFT
(N=7)
4.2±0.3*

PASS-IMM /
GRFT
(N=7)
4.5±0.2

PVALUE
0.0071

ALKP

U/L

16-302

82±13

62±22

97±33

94±30

0.0767

ALT

U/L

20-61

100±29

74±19

79±45

72±22

0.3717

AMYL

U/L

326-2246

1336±155

1577±236

1554±180

1681±190*

0.0468

CA

mg/dL

5.3-11.6

12.2±0.4

12.3±0.7

12.0±0.3

12.1±0.5

0.7027

CHOL

mg/dL

20-92

96±20

116±15

105±12

110±12

0.1292

CREA

mg/dL

0.1-0.6

0.3±0.1

0.4±0.1

0.4±0.0

0.3±0.1

0.1103

GLU

mg/dL

50-135

194±53

153±30

153±29

151±44

0.1898

PHOS

mg/dL

5.8-11.2

10.4±1.8

8.4±0.9*

8.4±0.9*

8.3±0.8*

0.0083

TBIL

mg/dL

0.1-0.7

1.9±1.8

1.0±0.6

0.6±0.2

0.9±0.8

0.1498

TP

g/dL

5.3-6.9

8.7±1.6

8.4±0.4

8.0±0.3

8.4±0.4

0.4511

BUN

mg/dL

9-21

21±4

19±2

23±2

23±3

0.0453

GLOB

g/dL

1.5-2.8

3.4±0.3

3.4±0.3

3.8±0.2

3.9±0.2*

0.002

Table 4.2. Serum Chemistry panels of animals after chronic treatment with PBS
or GRFT. Data represent mean values +/- standard deviation for albumin (alb),
alkaline phosphatase (ALKP), Alanine Transferase (ALT), amylase (AMYL),
calcium (Ca), cholesterol (Chol), Creatinine (Crea), glucose (Glu), phosphorus
(Phos), total bilirubin (Tbil), total protein (TP), blood urea nitrogen (BUN), and
globulin (Glob). One-way ANOVA with Bonferroni post-test significance versus
PBS-treated controls (p<0.05) is indicated by (*)
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PARA
METER
G-CSF

PBS
11.07±2.88

GRFT
17.25±10.48

PRE-IMM /
GRFT
16.82±19.07

PASS-IMM /
GRFT
19.97±10.16

P-VALUE
0.8646

EOTAXIN

6.12±3.09

8.11±4.32

9.24±4.16

10.06±2.36

0.2805

IL-1A

160.87±145.05

75.97±66.76

60.29±28.39

94.75±59.74

0.2139

LEPTIN

29769.12±4573.37

15093.69±8081.77*

17452.83±3928.75*

13823.71±4018.78*

<0.0001

MIP-1A

27.02±7.04

22.27±5.93

45.74±19.89*

28.52±9.83

0.018

IL-4

23.18±11.93

29.70±14.74

31.21±11.22

35.39±10.58

0.3748

IL-1B

126.22±90.19

20.06±16.42

67.74±71.77

54.67±64.93

0.1005

IL-2

68.46±28.80

92.71±63.96

72.42±14.68

83.74±25.80

0.6546

EGF

234.22±202.76

369.13±181.41

323.71±62.11

192.58±112.08

0.3922

IL-10

62.56±37.53

38.97±24.24

57.93±57.56

57.75±41.47

0.8135

IL12P70

69.77±26.86

82.26±38.17

103.65±34.89

89.89±32.31

0.3447

INFY

96.21±49.15

128.52±48.54

145.08±87.45

101.58±61.76

0.5661

IL-5

56.80±26.85

75.98±15.23

78.64±16.99

77.47±20.71

0.2062

IL17A

29.62±7.34

37.78±14.70

39.32±16.55

38.64±10.97

0.535

IL-18

506.12±138.40

312.26±297.23

472.82±228.10

350.87±145.14

0.3132

MCP-1

475.58±51.96

776.67±114.72

741.03±250.03

748.33±291.64

0.0568

IP-10

185.99±42.48

129.70±22.16*

166.04±44.34

173.19±17.32

0.0312

GRO/KC

116.17±21.69

75.73±16.15

72.99±46.29

75.60±32.01

0.0702

VEGF

54.01±12.05

52.53±13.22

56.39±9.94

62.53±14.70

0.4857

FRACTALK
INE
LIX

73.31±19.45

74.41±21.88

79.95±19.41

86.25±13.81

0.5796

2914.53±183.04

2776.74±390.75

2552.78±585.48

2700.44±326.32

0.4544

MIP-2

120.76±37.95

87.81±22.32

137.91±48.82

90.32±25.71

0.0382

TNFA

6.72±3.38

9.96±4.30

11.17±4.12

11.45±3.05

0.1285

RANTES

1984.74±534.73

1598.93±603.17

1696.66±667.23

1667.29±514.59

0.6658

Table 4.3. Cytokine levels after chronic administration with GRFT. Cytokine levels in serum from
rats 24 hours after treatment was quantitated. Analytes with three or more positive signals per
group: granulocyte colony-stimulating factor (G-CSF), Eotaxin, Granulocyte macrophage colonystimulating factor (GM-SCF), Interleukin 1 alpha (IL-1a), Leptin, Macrophage Inflammatory
Protein 1 alpha (MIP 1-a), Interleukin 4 (IL-4), Interleukin 1 beta (IL-1B), Interleukin two (IL-2),
EGF, Interleukin 13 (IL-13), Interleukin 10 (IL-10), Interluekin 12 (IL-12p70), Interferon gamma
(INFy), Interleukin 5 (IL-5), Interleukin 17 alpha (IL-17A), Interleukin 18 (IL-18), monocyte
chemoattractant protein 1 (MCP-1), interferon gamma induced protein 10 (IP-10), growth-related
oncogene (GRO/KC), vascular endothelial growth factor (VEGF), Fractalkine, lipopolysaccharide
induced CXC chemokine (LIX), macrophage inflammatory protein 2 (MIP-2), tumor necrosis
factor alpha (TNFa), and Rantes. One-way ANOVA with Bonferroni post-test analysis indicating
significance vs PBS treated controls (p<0.05) is indicated by (*).
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CHAPTER 5
CHARACTERIZATION OF BIOCHEMICAL INTERACTIONS OF GRIFFITHSIN
THROUGH DIFFERENTIAL SCANNING FLUORIMETRY, AFFINITY
PURIFICATION, AND DIFFERENTIAL SCANNING CALORIMETRY
INTRODUCTION

GRFT is a 12.7 kDa carbohydrate binding protein derived from the red algae
Griffithsia sp [32]. GRFT displays a strong affinity for N-linked oligomannose
glycans (Man5-9GlcNAc2) constituting glycan shields of multiple viruses, making it
a strong candidate as an antiviral microbicide and/or therapeutic [163, 164].
Notable antiviral activity has been observed in the case of HIV-1, HCV, Herpes
virus, SARS-CoV, and influenza [23, 30, 36, 171, 173]. Given this broad
spectrum antiviral activity, research into GRFT’s suitability as a systemic antiviral
prophylactic is ongoing. Previous in vitro studies have demonstrated that GRFT
possesses a favorable toxicity profile, suggesting its viability as a systemic
therapeutic. For example, GRFT is neither mitogenic, strongly immunogenic, nor
a strong inducer of inflammatory cytokines in human peripheral blood
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mononuclear cells [35, 169]. Further, previous studies into the impact of in vivo
administrations of GRFT have also been promising. GRFT shows in vivo activity
against JEV, HCV and SARS-CoV in mouse models [23, 30, 31, 173]. GRFT was
also tolerable in a 10-day acute subcutaneous administration study involving both
mice and guinea pigs [34].
Recently, we confirmed that GRFT was tolerable over the course of a 55day chronic administration study in rats, with minimal systemic toxicity reported
(manuscript in preparation). Interestingly, in prior studies active GRFT
concentrations were observable in treated mice and guinea pigs for many days
(up to 14 days in mice) after subcutaneous administration[34]. An additional
study into GRFT’s pharmacokinetics also displayed a rapid elimination or
degradation of GRFT following subcutaneous or intravenous administration
(manuscript in preparation). However, in that study, active concentrations of
GRFT were still detectable at potentially therapeutic levels up to 96 hours
following systemic administration. Given GRFTs observed serum persistence
and its increasingly recognized potential as a systemic anti-viral therapeutic,
further investigation into GRFT’s potential binding activity, binding partners, and
serum interactions are necessary.
A number of methods exist which can elucidate potential protein-ligand
interactions, potential protein-protein interactions, and changes in serum protein
interactions, thus allowing full characterization of the protein of interest. These
include Differential Scanning Fluorometry, Affinity Purification, and Differential
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Scanning Calorimetry. We utilized these techniques to gain greater insight into
GRFT’s potential interaction with endogenous proteins and ligands.
Differential scanning fluorimetry (DSF) is useful to measure protein-ligand
interactions. DSF has been used to identify potential ligand interactions,
including polysaccharide, peptide, and nucleic acid interactions with proteins, in a
high-throughput manner [212-217]. Given that ligand binding can increase
protein stability, shifts in fluorescence of hydrophobic dyes can be used identify
specific binding [214]. In the presence of a ligand, increases in melting
temperature (Tm) are observed which can yield data for identifying ligands which
may bind to, and stabilize, the protein. Thus DSF can screen for ligand binding
interactions which tend to stabilize a protein. Functionally, DSF measures the
temperature at which a protein melts through the use of a fluorescent dye, such
as SYPRO Orange, which possesses an affinity for hydrophobic regions of a
protein [215]. This process, conducted with a PCR instrument in microplate
format, provides for a high-throughput manner by which identification of specific
protein-ligand interactions can be measured.
Affinity Purification (AP) can identify stable protein-protein interactions. One
form, Tandem Affinity Purification has been used successfully to purify proteins
for identification by Mass-Spectrometry [218-224]. In another type of AP, a
recombinant “bait” protein is used to pull down proteins and protein complexes
from biological samples, and these interacting proteins are identified
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by Mass Spectrometry [225, 226]. While a number of tags have been identified
for this process, FLAG tagging of a bait protein has been used in AP with
success [221, 223].
Finally, differential scanning calorimetry (DSC) is a novel and effective
method to explore endogenous protein interactions in serum or plasma. There
are over 3000 different proteins in plasma or serum. However, the majority of the
proteomic mass consists of 22 proteins, while all the others are in relatively very
low abundance [227, 228]. DSC generates an excess specific heat capacity
profile, represented as a thermogram, of the most abundant proteins present in
plasma or serum[229]. These thermograms represent the weighted average of all
the major serum proteins interactions [230]. Alterations in thermograms from a
“normal” curve generated from healthy subjects represent changes in major
serum protein interactions [231]. The interactome hypothesis holds that low
molecular weight proteins or peptide binding to more abundant serum proteins
can alter normal serum protein interactions and thermostability [232].
DSC has been used to identify significant differences between the healthy
and disease thermograms in conditions such as rheumatoid arthritis, lupus
erythematosis, and Lyme disease [229, 230, 233-235]. Furthermore, DSC has
been proven to effectively identify changes in thermogram shapes indicative of
degrees of disease state in cervical cancer [231]. Therefore, we hypothesized
that DSC would be a useful additional tool in determining whether systemic
GRFT administration alters endogenous serum protein interactions, which in turn
could lead to identification of unseen toxicities associated with GRFT treatment.
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By employing DSF, AP and DSC to study GRFT’s potential biochemical
interactions, we have confirmed potential binding activity beyond oligomannose
moieties, identified a number of putative serum binding partners in human serum,
and demonstrated that GRFT spiked into rat serum in vitro does not appear to
impact serum protein interactions. However, calorimetric analysis of serum from
prior in vivo experiments involving chronic subcutaneous administration of GRFT
in rats revealed changes in serum thermograms. These results suggest that
protein and/or protein-glycan binding may be a mechanism by which GRFT
persists in serum. Further, GRFT by itself does not appear to perturb serum
protein interactions. However, it appears that GRFT administration in vivo may
induce changes in serum protein binding interactions, though the mechanisms
and impact of these interactions will require further study.
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MATERIALS AND METHODS
Lectin reagents
Recombinant GRFT or GRFTlec- (a non-binding protein control in which
lectin binding sites are eliminated) was produced in Nicotiana benthamiana as
described previously, purified to >99% purity, and formulated in phosphate
buffered saline (PBS), pH 7.4 [169].

Tandem Affinity Purification Lectin reagents
Linear fusions of GRFT or GRFTlec- (a non-binding protein control in which
lectin binding sites are eliminated) homodimers with a C-terminal FLAG tag and
N-terminal 6xHis tag were cloned by a collaborator (manuscript in preparation)
into Icon Genetics vector pICH11599. A three-component vector system was
used for expression. Agrobacterium tumefaciens containing the gene of interest,
integrase, and cytosolic were infiltrated into 28 d.p.s. (days post sowing) N.
benthamiana plants. Five days after infiltration, treated N. benthamiana plants
were harvested and ground in 20 mM sodium phosphate, 500 mM NaCl, 20 mM
imidazole, ascorbic acid, sodium metabisulfite, 8M urea, pH 7.4 at 0.5g product
per 1ml buffer. The extract was filtered over a 1 filter press and the subsequent
cake washed with 25% volume of buffer. The extract was again filtered through a
0.5 filter press and washed with 25% volume of buffer. To prepare for
chromatography, extracts were filtered through a 0.2 bottle top filter and purified
over nickel sepharose GE with a one-step elution gradient to 20 mM sodium
phosphate, 500 mM NaCl, 250 mM imidazole, pH 7.4. Elution fractions were
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pooled and diluted 10X with PBS to prepare for FLAG column (Sigma)
purification.

DSF reagents
The lectin binding capacity of GRFT and GRFTlec- was examined by using
SYPRO Orange thermal shift assays. Briefly, SYPRO orange (Sigma) was
diluted to 400x concentration in PBS, pH 7.4. GRFT and GRFTlec- were diluted to
125 uM concentrations. Serial dilutions of the following potential ligands were
formulated in PBS: mannose, maltose, glucose, N-acetylglucosamine heparin,
mannan, and alpha 1,2 mannobiose.
Samples for protein melt analysis were formulated using 29.05 µL of
GRFT or GRFTlec-, 8.75 µL of diluted SYPRO orange, and 32.2 µL of ligand
dilutions to yield at total volume of 70 µL sample. 20 µL of each sample were
loaded in triplicate into a 96-well PCR plate (NUNC).
Samples were analyzed by an Applied Biosystems StepOnePlus real-time
PCR system. Temperature range studied was 20C to 95ºC, incrementally raised
0.2ºC/15 seconds. The effect of saccharide binding on protein melting was
determined by changes in fluorescent signal as the sample was heated to 95ºC.
Controls consisting of highest saccharide concentrations containing no GRFT or
GRFTlec- were used to determine baseline fluorescence of the ligands, if any.
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Affinity Purification – Human Serum
Affinity Purification of GRFT-protein complexes was facilitated by use of
GRFT or GRFTlec- containing a His/FLAG tag as a “bait” protein. Briefly, 500 µL of
Anti-FLAG M2 resin (Sigma) was loaded into 2 ml gravity flow columns (Fisher).
Columns were equilibrated by running 5 column volumes of Tris Buffered Saline
(pH 7.4) through the column resin. For bait containing columns, 300 µg aliquots
of FLAG-GRFT or FLAG-GRFTlec- protein was then run through respective AntiFLAG gravity columns a total of four times to ensure all FLAG fusion proteins
were bound to the resin. A resin-only control column was used to assess nonspecific resin binding.
Human serum (Innovo Research) was diluted five-fold in PBS and run
through the column by gravity filtration. After serum was run through the
columns, the column resins were washed with 20 column volumes (40 ml) of
TBS, pH 7.4. Isolated proteins were eluted by the addition of 8mL of 0.1M
glycine HCL pH 3.5, collected in 8, 1 ml fractions. Each 1 ml fraction was
collected in Eppendorf tubes containing 10 µL of 1 M Tris-HCL pH 9.0. Columns
were re-equilibrated by running 10 column volumes of TBS pH 7.4 through the
column. Elution fractions were analyzed for protein content by Nanodrop. The
highest protein containing fractions were analyzed by Mass Spectrometry.
Proteins in selected elution fractions were identified by ElectroSpray
ionization, liquid chromatography and tandem mass spectrometry (Mary
Gawinowicz). Briefly, 100 µL of sample was combined with 200 µL 8M urea in
0.1M Tris-HCl, pH 8.5. Diluted sample was then added to the filter unit of a
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Microcon YM-10 cartridge (Millipore) and centrifuged at 14,000 x g for 10
minutes. 250 µL of 8M urea in 0.1M Tris-HCl, pH 8.5, was added to the filtration
unit and centrifuged again. The final volume of the sample was 40 µL. The flow
through was discarded. The concentrated sample in the filter unit was diluted
with 60 µL 8M urea in 0.1M Tris-HCl, pH 8.5 and 10 µL of 0.1M DTT added. The
solution was kept at 60°C for 1h and then cooled to room temperature. The
sample was alkylated by adding 10 µL of 0.15M iodoacetamide. The reaction
was allowed to proceed in the dark for 30 minutes. The sample was then diluted
with 100 µL 1M urea in 0.1M Tris-HCl, pH 8.5 and centrifuged at 14,000g for 10
minutes, followed by another addition of the same buffer and centrifugation at
14,000g. The process was repeated once. The remaining sample solution in the
filter unit was collected and diluted to 50 µL with 1M urea in Tris-HCl, pH 8.5.
Trypsin (Roche Biochemicals, sequencing grade), 0.2 µg in 20 µL 0.1M Tris-HCl,
pH 8.5, was added and the solution incubated at 32°C overnight. The digested
solution was desalted with a C18 tip and dried in a Speed-Vac concentrator. The
digest was redissolved in 20 µL 0.2% formic acid and 5 µL injected onto the LCMS.
LC-MS/MS was conducted on a Waters Q-Tof Ultima hybrid
quadrupole/time-of-flight mass spectrometer with a nanoelectrospray source.
Capillary voltage was set at 1.8kV and cone voltage 32V; collision energy was
set according to mass and charge of the ion, from 14eV to 50eV.
Chromatography was performed on an LC Packings HPLC with a C18 PepMap
column using a linear acetonitrile gradient with flow rate of 200 nl/ min.
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Raw data files were processed using the MassLynx ProteinLynx software
and .pkl files were submitted for searching at www.matrixscience.com using the
Mascot algorithm.

DSC- Rat Serum Spiking
For generation of rat serum thermogram profiles after spiking with PBS or
GRFT, the protocol for sample preparation and dialysis described by Garbett et
al. was used [231]. Briefly, a standard phosphate dialysis buffer (1.7 mM
KH2PO4, 8.3 mM K2HPO, 150 mM NaCl, 15 mM Na3C6H5O7, pH 7.5) was
formulated and rat serum was dialyzed for a period of 24 hours at 4ºC to
normalize buffer conditions. Serum was thawed overnight at 4ºC the night before
dialysis. After thawing, 100 µL aliquots of rat serum (Sigma) and an aliquot of
100 µL of 10.8 mg/ml GRFT were loaded into Slide-A-Lyzer mini-dialysis units
(MWCO 3500; Pierce, Rockford, IL) and dialyzed at 4ºC against 1L of buffer with
changes occurring at 3 hours, 7 hours, 11 hours, and overnight. Following
dialysis, serum was filtered through a Spin-X centrifuge 0.45 micron centrifuge
tube filter and 99 µL aliquots were made for spiking with GRFT or PBS. Final
dialysis buffer, to serve as a reference and diluent for sample dilutions, was
filtered using a 0.2 µm rapid flow filter and stored at 4°C.
Dialyzed GRFT dilutions in PBS were prepared ranging from 10,000 nM to
50 nM. Dialyzed serum aliquots were spiked with GRFT or PBS by the addition
of 2 µL of GRFT dilution or PBS to 98 µL of dialyzed serum. The resulting final
concentrations ranged from 1 nM to 1000 nM, to exceed the upper molarities of
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GRFT concentrations previously observed after subcutaneous dosing in prior
studies [34]. Samples were allowed to react at 4ºC for one hour. Spiked serum
samples were diluted in dialysis buffer (1:25) and samples and reference
diasylates were loaded into a 96-well plate and loaded into the instrument
autosampler thermostatically set at 4ºC.
DSC data were collected with a NanoDSC (TA Instruments). Scans were
recorded from 20ºC to 100ºC at a scan rate of 1c/ per minute. Duplicate scans
were obtained for all samples. Excess specific heat readings for samples and
reference buffers were recorded.

Baseline corrected scans were obtained by

subtracting a suitably adjacent reference buffer-buffer scan from the raw scans.
Scans were further normalized for total protein concentration. Total protein
concentrations were determined using Pierce bicinchoninic acid protein assay
key and modified microplate procedure. Scans were corrected for non-zero
baselines using Origin 7 for linear baseline fitting. Interpolated, final thermograms
were calculated and average scans calculated from the duplicates were plotted
as excess specific heat capacity versus temperature.

DSC – Chronically Dosed Rat Serum
In a previous study (manuscript in preparation), age-matched Sprague
Dawley rats were subcutaneously treated with either PBS or 10mg/kg GRFT
every three days for 51 days. A group of passively-immunized animals also
received 1.4 mg of anti-GRFT Ig formulated in 1 ml of PBS every 14 days.
Additionally, one group animals was pre-immunized for 6 weeks prior to the study
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with GRFT and Sigma adjuvant to prime an immune response to GRFT prior to
treatment initiation. Blood was drawn via lateral tail vein on the following days:
Day 10, 24, 38, and 52, with sacrifice on day 55 via CO2 asphyxiation followed by
cardiac puncture exsanguination. Serum was separated from blood samples
following coagulation by centrifugation and stored at -20ºC until needed. Given
the timing of blood draws in relation to last administration of GRFT or PBS, Bleed
1(day 10) and Bleed 4 (day 52), both 24 hours after administration, were selected
for calorimetric analysis.
As described previously, samples were thawed at 4ºC overnight before
dialysis. Samples were dialyzed into standard phosphate buffer for 24 hours with
four buffer changes. Following dialysis, serum samples were diluted in dialysis
buffer (1:25) and excess specific heat readings at temperature ranges from 20°C
to 100°C were determined. Duplicate runs were completed and average
baseline corrected, protein normalized, interpolated values for each sample were
generated.

Data Analysis
Preliminary examination of DSF curves revealed a dynamic range of 4595ºC. Accordingly scans were truncated to this range for all analysis. Melting
transition temperatures (Tm) for each curve was determined using GraphPad
5.01 and Boltzmann Sigmoidal non-linear fit template available at
ftp://ftp.sgc.ox.ac.uk/pub/biophysics/GraphPad_templates/. Mean T m values for
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GRFT and GRFTlec- were determined for pure protein and each ligand
concentration.
Proteins recovered by AP were identified by Mascot algorithm. However,
not all proteins identified were deemed a reliable “hit”. Proteins identified were
filtered by both Mascot score and number of “significant” ion matches to increase
positive identification confidence. Given that a significant peptide ion match could
appear in more than one protein, a minimum of 3 significant (p<0.05) peptide ion
matches for a particular protein identified and a minimum Mascot score of 90
were used as thresholds for filtering. Proteins identified were grouped by bait
protein used (FLAG-GRFT, FLAG-GRFTlec-, or resin-only).
Preliminary examination of DSC thermograms revealed a dynamic
temperature range of 45 to 90ºC for the serum thermogram curves. Accordingly,
scans were truncated to this range for all analysis. Quantitative comparisons of
the thermograms were accomplished through calculation of shape and feature
metrics as well as selection of points of interest within the dynamic range of the
thermogram curve. Parameters considered included: total area under the curve
(AUC), maximum curve height (Cpex), temperature at max height (Tmax) Curve
width at half height (width), maximum peak height at the 60-67C range (Cpex1),
maximum peak height of the secondary peak at the 68-72C range (Cpex2), and
ratio of the first and second peak amplitudes, and first moment temperature (Tfm).
The first moment temperature (Tfm), used to analyze geometric area distribution
changes, was calculated as described by Garbett [231]. Additionally, excess
specific heat capacities were analyzed for the following temperature points: 55,
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60, 65, 67, 70, 75, and 80ºC. Finally, a composite 'similarity metric' developed by
a collaborator (Dan Fish) was generated for each curve [234]. This metric is a
combination of an average z-scores or p-values for all temperature points,
assuming a normal distribution of the control curve, and a correlation measure,
allowing a comparison of test curves versus an average control curve. Similarity
scores for each curve were generated. Mean similarity scores were then
analyzed by one-way ANOVA with Bonferroni posttest analysis to determine
which groups were changed, if any.
Thermogram parameters were grouped by treatment group and
differences in thermograms were assessed by ANOVA with post-test to identify
changes in groups. A p-value of <0.05 was deemed significant. Statistical
analysis was conducted using GraphPad 5.
For Day 52 thermogram parameters, correlations between certain curve
parameters and serum data previously seen for Day 55 terminal bleeds (Barton)
of the same animals were evaluated. Pearson Correlation Coefficients and pvalues were generated using GraphPad 5.
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RESULTS
DSF
Ligand free, protein-only controls consisting of GRFT or GRFTlecdisplayed marked differences in melting profiles, with GRFT’s Tm at
approximately 75.65ºC and the Tm for GRFTlec- at approximately 80.68ºC
(Figure 5.1, Table 5.1).
Further differences in GRFT and GRFTlec- fluorescence signals were
observed in response to varying ligand concentrations (Figure 2). GRFT
displayed substantial shifts in melting temperature in response to 460 mM
concentrations of glucose, maltose, mannose, and N-acetyl glucosamine with
shifts in Tm from 9 to 11ºC (Figure 5.2 and Table 5.1). Furthermore, GRFT
displayed shifts of >1ºC in melting temperature at 46mM concentrations of those
saccharides as well as 2.3 mg/ml and 230 µg/ml concentrations of mannan
(Figure 5.2B and Table 5.1). In contrast, high concentrations of all ligands
shifted the melting temperatures for GRFTlec- by less than 2ºC (Table 5.1).
Further, at lower concentrations of ligand, no positive shifts were observed in
GRFTlec-.

Affinity Purification
Purification of human serum proteins using FLAG-GRFT and FLAGGRFTlec- bait proteins was successful, though the majority of the proteins
identified were Ig chains or albumin. MS/MS analysis of the elution fractions
revealed a number of proteins were retrieved from human serum. After
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eliminating keratinocyte-related proteins and filtering by Mascot score and >2
significant peptide ion hits, a number of candidate binding partners for each
purification condition were identified (Table 5.2). Designating and Eliminating
proteins bound to resin as nonspecific background revealed proteins/protein
complexes interacting with FLAG-GRFT, FLAG-GRFTlec-, as well as both FLAGGRFT and FLAG-GRFTlec- (Table 5.3).

DSC - GRFT and PBS spiked rat serum
Rat sera spiked with varying concentrations of GRFT did not display a
substantial shifts in thermograms versus PBS-spiked control serum. (Figure 5.3).

DSC– Chronically Treated Rats
Mean treatment group thermogram curves were generated for bleed 1
(day 10) and bleed 4 (day 52) (Figure 5.4A and B, respectively). Standard
deviation of mean group thermograms from both time points were generated for
visual inspection. (Figure 5.4C and D) Analysis of thermogram area (Figure
5.5A), max height (Figure 5.5B), Tmax (Figure 5.5C), or peak ratios (Figure 5.6C)
did not reveal any significant differences between groups on either day 10 or day
52. Further, peak heights were not significantly different among groups at day 10
(Figure 5.6A). However, differences were observed in Width, Cpex1, and Tfm for
day 52 curves. Day 52 widths were significantly different (p=0.0266), with both
pre-immunized and passively immunized animals displaying smaller widths in
comparison to PBS-treated controls (Figure 5.5D). Cpex1 heights in the 60-68ºC
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range were also significantly different for day 52 samples, with passively
immunized animals displaying a significantly decreased (p=0.0389) maximum
peak height in that temperature range (Figure 5.6B). Finally, Tfm were
significantly reduced in GRFT treated groups vs. PBS treated controls (Figure
5.6D, p=0.0179).
Analysis of group excess specific heat capacities at selected temperatures
did not reveal any differences among the groups at day 10 (Figure 5.7A).
However, day 52 groups were significantly different at both the 67ºC (p=0.03)
range as well as the 75ºC temperature (p=0.004). (Figure 5.7B).
Overall curve similarity scores did not reveal significant differences among
treatment groups on day 10, though results did approach significance (Figure 8).
However, significant differences between groups were observed on day 52
(p=0.0069). Which? Post-test analysis revealed significant differences in both
GRFT and passively-immunized groups in relation to PBS-treated controls.
Pearson correlation analysis among day 52 curve parameters and day 55
serum characteristics revealed both significant positive and negative correlations
(Table 5.4). Significant positive correlations were observed between the
following parameters (correlation coefficient, p-value): Albumin and Total Protein
(0.85,p<0.0001), Area and Width (0.44, p=0.0321), Area and Max Peak(0.92,
p<0.0001), Globulin and Total Protein (0.49, p=0.0189), Globulin and Anti-GRFT
antibody titers (0.45, p=0.0375), Globulin and Tfm (0.50, p=0.0145), and Tmax and
Tfm (0.52, p=0.0095). Significant negative correlations were observed between:
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Albumin and Anti-GRFT antibody titers (-0.50, p=0.0188), Width and Tfm (-0.56,
p=0.0041), and Pseudovirus neutralization activity and Tfm (-0.54, p=0.0094).
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DISCUSSION
Potential protein and ligand interactions can be of physiological relevance
for a new therapeutic. Accordingly, identification of interaction potential can be
useful. DSF analysis of both GRFT and GRFTlec- showed differences in melting
points as well as differences in binding of various saccharides. Analysis of
fluorescence curves showed that ligand-free GRFT displayed a consistent
melting transition temperature at approximately 75 degrees, whereas GRFTlecdisplayed a melting temperature of approximately 80 degrees (Table 5.1). This
difference in melting temperature given the modest changes to the protein would
suggest that ablation of lectin binding sites result in increased protein stability, an
effect also generally theorized to occur when protein binding sites are occupied
by ligand [212, 214].
Positive shifts in melting temperature as a result of saccharide binding
with GRFT and GRFTlec- were also observed. Ligand binding to a protein’s active
site will normally increase stability, leading to increase the protein melting
temperature. Accordingly it was expected that specific saccharide binding to
GRFT’s lectin binding sites would result in higher transition temperatures. This
was confirmed by the marked increases in melting temperatures of GRFT upon
addition of glucose, maltose, mannose, mannan, and N-acetylglucosamine.
While of much lower affinity than oligomannose, interactions between GRFT and
these carbohydrates have been observed in other studies [164, 166]. Although
GRFT binds strongly to oligomannose glycans [163] via its jacalin-like
carbohydrate binding sites, weaker or transient interactions with other
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endogenous saccharide moieties cannot be ruled out and may help to explain
GRFT’s long serum persistence observed in other studies [34]. Further, similar
marked differences in melting temperature was not observed for GRFTlec- for all
saccharide concentrations. While GRFTlec- displayed a higher baseline melting
temperature, it only displayed a modest (<2ºC) shifts in melting temperature at
the highest saccharide concentrations. This is in stark contrast to the greater
(>9ºC) shifts observed in GRFT at comparable concentrations. These data
confirm that a range of weaker potential saccharide binding partners for GRFT
exist and may be relevant to GRFT’s serum stability. Interestingly, high heparin
concentrations decreased GRFT’s Tm, suggesting some level of destabilizing
effect. However, how and why this destabilization occurs is currently unknown.
In addition to interacting with saccharide moieties, GRFT’s ability to
effectively bind to human serum proteins was confirmed by its interaction in the
FLAG-GRFT serum capture columns. While some off-target serum binding was
observed in the resin-only serum capture, a number of unique proteins, including
lipoprotein and complement proteins, were captured by FLAG-GRFT bait.
Further, FLAG-GRFTlec-, also captured a number of proteins, including some that
were unique to GRFTlec-. FLAG-GRFT and FLAG-GRFTlec- differ only in the
lectin binding motifs, therefore capture of unique serum proteins by FLAG-GRFT
indicates a binding mechanism which requires active lectin binding sites. We
hypothesize that those proteins captured by both FLAG-GRFT and FLAGGRFTlec- may suggest alternative, non-lectin mediated binding mechanisms or
binding of the serum proteins to structural motifs on the bait proteins. However,
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the specific nature of each protein’s interaction will need further investigation.
Additionally, a SwissProt search of post translation modifications typical to the
recovered serum proteins also revealed a varying number of N-linked glycans
present on the proteins. However, the vast majority of glycans noted were of the
N-linked, complex variety. These data, together with saccharide binding data
from DSF, indicates that GRFT binds an array of serum proteins, and is not
limited to those possessing oligomannose glycans.
Interestingly, a larger percentage of proteins bound exclusively by GRFT
were complement proteins and apolipoproteins, attractin, and vitronectin. The
mechanism of these binding interactions will need to be confirmed by other
binding methods to determine whether they are recovered as a part of a
complex, however based upon their exclusive recovery by the FLAG-GRFT
column, it appears that they will likely involve the lectin binding sites of GRFT.
For instance, the presence of proteins possessing no N-linked glycans, as in the
case of Apolipoprotein A-II is suggestive of entire protein complexes being
precipitated from serum via this method. Interestingly, despite apparent binding
activity with apolipoproteins, cholesterol changes in guinea pigs and rats have
not been noted [34] (and manuscript in preparation). Further, given continued
antiviral activity observed in serum following systemic administration[34] (and
manuscript in preparation), it does not appear that this binding interaction
substantially impairs GRFT’s antiviral activity. However, complement interactions
may be problematic. Complement proteins are important in the innate immune
response to pathogens. Accordingly, a binding interaction with these proteins
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could have deleterious effects if it binds in a manner so as to inhibit pathogen
recognition or cause functional deficiency of particular complement proteins [236240]. For instance, deficiencies in complement 2 and 4 have been associated
with autoimmune diseases, particularly systemic lupus erythematosus [240-242].
Whether these binding interactions cause functional depletion or complement
activation will require further study. However, it is entirely possible that this
binding activity may be related to the potential immunosuppressive and antiinflammatory effects of GRFT observed in previous long term systemic studies of
GRFT in rats.
GRFT’s long serum persistence has been observed in our prior studies. It
is believed that these protein-protein interactions may be crucial in maintaining a
baseline serum concentration of GRFT. Further enhancing these interactions
may be useful in exploring GRFT’s potential as a long-term systemic preexposure prophylactic.
Calorimetric analysis of spiked rat serum and analysis of samples from a
GRFT chronic dosing study in rats also yielded notable results. Spiking large
concentrations of GRFT into rat serum did not appreciably change serum
thermograms in comparison to the PBS spiked controls (Figure 5.3). This would
seem to indicate that GRFT’s presence by itself does not disturb major serum
protein interactions. However, thermograms of sera from animals chronically
treated differed depending on the duration of GRFT treatment (Figure 5.4A). Both
visual inspection of mean thermogram curves and statistical analysis consistently
showed no significant differences on day 10 other than first moment
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temperatures. Notably, Bonferroni post-test analysis failed to identify which
groups were different. However, passively and pre-immunized animals displayed
lower mean Tfm than PBS treated controls. It is hypothesized that these first
moment temperature decreases would indicate an increase in overall area at
lower temperature ranges, possibly by a greater contribution to area of the mean
curve by immunoglobulins (as elevated IgG levels was the aim of preimmunization, and the effect of passive immunization). Further study will be
necessary to see if this redistribution of curve area was due to an increase in
IgG, IgM, or some other immunoglobulin in those treatment groups.
In stark contrast with day 10 samples, significant changes were induced
by day 52. Visual examination of the mean group thermograms revealed notable
differences and statistical analysis of day 52 curve parameters revealed multiple
changes in treatment group thermograms vs. PBS-treated controls. Categories
such as Width, Cpex1, and Tfm were significantly different among treatment
groups, which could indicate stabilizing protein interactions with major serum
proteins, shifting the area of the curve to higher temperatures while narrowing the
width of the curve. Stabilization of serum proteins is thought to result in an
increased shift of their melting to higher temperatures. A destabilization of
endogenous serum protein interactions should result in shifting of thermograms
to lower temperatures. Of the serum parameters examined for day 52 samples,
GRFT-only treatment appeared to result in a downshift of Tfm not observed in
other groups, suggesting a destabilizing alteration of serum protein interactions.
Further, the Tfm did not display a similar shift in pre-immunized or passively
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immunized animals at that time point. Nonetheless, those groups did display
changes in width, with passively immunized animals also displaying a decrease
in Cpex1. Analysis of excess specific heat capacities at specific temperatures
revealed few differences, with the only changes seen between Passively
Immunized/GRFT-treated animals vs PBS controls at 67ºC and 75ºC, and a
difference between GRFT-treated vs. PBS controls also observed at 75ºC.
The broadest measure of differences between groups appeared to be
accomplished by the generation of similarity scores relative to a mean control
curve. Day 10 curves differences approached significance, with GRFT-only and
GRFT/passively immunized curves displaying the greatest degree of difference
versus mean controls. However, by Day 52, the differences are much more
substantial. Similarly to day 10, GRFT-only and GRFT/Passively immunized
groups displayed very significant changes vs. PBS-treated controls. This
difference is not observed in the group which was pre-immunized with GRFT and
adjuvant prior to initiation of treatment. Further, in both cases, similarity scores
for pre-immunized animals revealed greater similarity to controls than either
GRFT or GRFT/passively immunized groups. As such, it would appear that preimmunization or priming of an immune response may blunt some of the
alterations in serum protein interactions. Prior studies have suggested that deimmunization of GRFT may be necessary to eliminate some of the changes
induced by systemic administration of GRFT [34, 161, 162]. However, these
data suggest that an immune response to GRFT may be protective of the
changes induced by systemic administration of the protein.
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Finally correlation analysis between selected day 52 curve parameters
and serum parameters from the same animals bled at day 55 revealed a number
of significant positive and negative correlations. These correlations assumed
non-rapid alteration of serum protein interactions over the intervening 3 day
period, and were necessary given exhaustion of day 52 and day 55 serum for
analysis. In many instances, correlations between total globulins, albumin, and
total protein were expected. Further, these correlations revealed increases in
globulin positively correlated with increased in T fm. However, no curve parameter
significantly correlated with anti-GRFT activity determined by antibody titer in a
previous study.
In conclusion, DSF and AP confirms that GRFT is capable of binding
saccharide moieties and proteins beyond those displaying high-mannose
(oligomannose) glycans [164, 166]. Further, in some instances, it appears that
GRFT may use lectin-binding sites to bind to endogenous serum proteins,
potentially through binding to other types of N-linked glycans. However, it is also
wholly possible that in some instances, GRFT is the “prey”, given the number of
proteins captured by both GRFT and GRFTlec-. These interactions may prove to
be the foundation of GRFT’s long serum persistence and further study may yield
insights into how GRFT’s serum persistence could be extended without the
sacrifice of anti-viral activity. Additionally, DSC results have shown that while
chronic GRFT administration has been observed as tolerable in other studies,
alterations to endogenous serum protein interactions may result as a
consequence of longer-term chronic treatment. However, these alterations do
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not appear to be due to the simple addition of GRFT into the system. These
results would indicate that GRFT administration results in an
induction/suppression of other proteins, alterations in the binding of lower
molecular weight proteins to the more abundant proteins, or alteration of higher
abundance protein proportions, to which DSC is extremely sensitive. Of note,
while still altered to a degree, animals pre-immunized with GRFT and adjuvant
consistently displayed less thermogram variation in contrast to GRFT-only or
GRFT/passively immunized treatment groups. This would seem to suggest a
protective immunological response, beyond simple production of
immunoglobulins. Further, based on prior findings, that response does not
appear to compromise antiviral activity. However, further study into exactly how
these changes are induced, as well as which proteins interactions are altered,
will need further study.
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Figure 5.1. GRFT and GRFTlec- SYPRO orange denaturation curves in the
absence of saccharide ligand. Ligand-free fluorescence curves generated by
thermal denaturation of GRFT or GRFTlec- in the presence of PBS and SYPRO
Orange.
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Figure 5.2. Protein stabilization effects of ligand binding on GRFT and GRFTlec-.
Fluorescence curves of GRFT and GRFTlec- in the presence of potential ligands
(A) and shifts in melting temperatures (Tm) (B).
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Table 5.1. Concentration dependent shifts in melting temperatures of GRFT and
GRFTlec- determined by SYPRO orange fluorescence shifts. Tm values,
representing melting temperatures for GRFT and GRFTlec- were determined in
the absence and presence of ligands. Tm change values were calculated for all
ligand concentrations by subtracting the Tm for GRFT or GRFTlec- in the absence
of ligand.
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Table 5.2. Proteins recovered from Human Serum by Affinity Purification with
FLAG-fusion protein. Proteins recovered by affinity purification with Anti-Flag
resin, FLAG-GRFT, or FLAG-GRFTlec- were identified by tandem mass
spectrometry and filtered by MASCOT score and >2 significant peptide ion hits.
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Unique Proteins Identified

FLAG-GRFT
Apolipoprotein
A-I
Apolipoprotein
A-II
Apolipoprotein D

Gly.
Sites
1N
(glycation)
0
2N

Attractin

26N

Complement C2

8N

Complement
C4-A
Vitronectin

4N,1O

lec-

FLAG-GRFT
Alpha-2macroglobulin
Ig gamma-4 chain C
region
Serotransferrin

3N

Gly.
Sites
8N

FLAG-GRFT and
FLAG-GRFTlecAlpha-1-antitrypsin

Gly.
Sites
3N

1N

Apolipoprotein B100
C4b-binding protein
alpha chain
Complement C3

19N

Complement factor
H
Haptoglobin

9N

Haptoglobin-related
protein
Ig mu heavy chain
disease protein
Immunoglobulin
lambda-like
polypeptide 5

0

3N,1O

3N
3N

4N

1N
0

Table 5.3. Unique proteins identified by affinity purification. Proteins were
recovered by affinity purification using Anti-FLAG resin, FLAG-GRFT, and FLAGGRFT. After filtering by Mascot score and >2 significant peptide ion hits,
background binding was determined by proteins binding to Anti-FLAG resin-only
controls. After elimination of proteins non-specifically binding to Anti-FLAG resin,
a number of proteins unique to FLAG-GRFT or FLAG-GRFTlec- were identified.
Glycosylation state was determined by SwissProt search.
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Figure 5.3. Thermogram profiles of rat serum spiked with varying concentrations
of GRFT. Thermogram profiles of excess specific heat capacity versus
temperature for rat serum spiked with a range of concentrations of GRFT.
Concentrations were final molarity concentrations of GRFT spiked into rat serum
before 25x dilution of samples for calorimetric analysis.
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Figure 5.4. Mean thermograms generated from sera from rats chronically treated
with Griffithsin or PBS. Mean thermogram profiles of excess specific heat
capacity (cal/°C.g) versus temperature for Day 10 (A) and Day 52 (B) serum
samples from animals chronically treated with PBS, GRFT, PreImmunized/GRFT-treated [Pre-imm], or Passively Immunized/GRFT-treated
[Pass-Imm]. Standard Deviation of excess specific heat capacity of each group
for day 10 (C) and day 52 (D) was generated for comparison.
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Figure 5.5. Thermogram shape and feature parameters for rats chronically
treated with GRFT or PBS. Values for Area (A), Height (B), Temperature at max
height (C), and curve width (D) were calculated for each thermogram generated
from serum from PBS [P], GRFT [G], Pre-immunized/GRFT-treated [Pr] and
Passively-immunized/GRFT-treated [Pa] animals. Mean values for treatment
groups determined for treatment day 10 and 52 were analyzed by one-way
ANOVA with Bonferroni posttest. Bars represent mean and standard deviation of
six biological replicates. A p-value of <0.05 was deemed significant (*).
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Figure 5.6. Peak and First-moment (Tfm) thermogram parameters for rats
chronically treated with GRFT or PBS. Values for Peak Heights on day 10 (A),
Peak heights on day 52 (B), Peak Ratios (C), and first moment temperatures (D)
were calculated for each thermogram generated from serum from PBS [P], GRFT
[G], Pre-immunized/GRFT-treated [Pr] and Passively-immunized/GRFT-treated
[Pa] animals. Mean values for treatment groups determined for treatment day 10
and 52 were analyzed by one-way ANOVA with Bonferroni posttest. Bars
represent mean plus standard deviation of six biological replicates. A p-value of
<0.05 was deemed significant (*).
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Figure 5.7. Distribution of Excess specific heat capacity for rats chronically
treated with GRFT or PBS at select temperature points. Excess specific heat
capacities on day 10 (A) and day 52 (B) for animals treated with PBS [P], GRFT
[G], Pre-immunized/GRFT-treated [Pr] and Passively-immunized/GRFT-treated
[Pa] at 55, 60, 65, 67, 70, 75, and 80ºC were determined. Whiskers indicate
Maximum and minimum values. Mean values were analyzed by one-way
ANOVA with Bonferroni posttest. A p-value of p<0.05 was considered significant
(*).

138

Figure 5.8. Thermogram similarity scores for sera from rats chronically treated
with PBS or GRFT. Similarity scores were calculated for each thermogram
generated from serum from PBS [P], GRFT [G], Pre-immunized/GRFT-treated
[Pr] and Passively-immunized/GRFT-treated [Pa] animals by statistical
comparison of curves versus a time-matched, mean PBS-treated control curve.
Mean similarity values for day 10 and 52 similarity scores were analyzed by oneway ANOVA with Bonferroni post-test. Bars represent mean plus standard
deviation of six biological replicates. A p-value of <0.05 was deemed significant
(*).
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TFM

PSV.
NEUT.

ANTIGRFT
TITER

WIDTH

TMAX

GLOB

T.P

MAX
PEAK

AREA

ALB.

0.02

-0.06

-0.50

0.13

0.34

-0.07

0.85

-0.27

-0.13

AREA

-0.19

-0.02

0.21

0.44

0.04

-0.21

-0.14

0.92

0.07

-0.14

0.23

0.12

0.03

-0.08

-0.19

0.28

0.04

-0.19

-0.08

0.35

0.49

GLOB.

0.50

0.12

0.45

-0.46

0.20

TMAX

0.52

-0.32

-0.05

-0.10

WIDTH

-0.56

-0.02

-0.05

-0.01

0.41

MAX
PEAK
TOTAL
PROT

ANTIGRFT
TITER
PSV.
NEUT.

-0.54

Table 5.4. Pearson Correlations of rat serum thermogram parameters and rat
serum characteristics. Day 52 thermogram parameters of Area, Max Peak, T max,
Tfm, and Width were compared with day 55 serum characteristics of Albumin,
Globulin, Total Protein (T.P), Anti-GRFT antibody titers, and pseudovirus
neutralization (Psv. Neut.) from the same animal. Pearson Correlation and pvalues were generated. A correlation having a p-value of p<0.05 was considered
significant.
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CHAPTER 6
SUMMARY OF GRFT RESEARCH AND IMPLICATIONS FOR FUTURE
RESEARCH

Throughout this work, we have analyzed GRFT’s biochemical interactions
and physiological profile in furtherance of our overarching hypothesis that GRFT
is a good candidate for antiviral prophylactic and therapeutics. A number of
hypotheses were explored. First, we hypothesized that GRFT would be orally
bioavailable after oral dosing. To test this hypothesis, we performed
pharmacokinetic testing as well as chronic oral dosing of GRFT. Next, we
hypothesized that chronic treatment of GRFT would be systemically tolerable.
To test this hypothesis, we conducted a 51 day treatment regimen with GRFT in
the presence and absence of a pre-existing immune response. Finally, given
data from prior experiments, we hypothesized that biochemical interactions of
GRFT may include specific binding interactions of importance. Further we
hypothesized that while GRFT treatment did not cause significant toxicities in
prior studies, perturbations in endogenous serum binding proteins may occur. To
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test these hypotheses, we conducted DSF, affinity purification of serum proteins,
as well as DSC analysis of serum from chronically treated rats. From the data
presented in this work, a number of conclusions can be drawn, which taken as a
whole, support the further study of GRFT as a systemic antiviral therapeutic.
GRFT persisted in the circulation similarly upon dosed subcutaneously and
intravenously.
Pharmacokinetic studies of GRFT’s elimination profile revealed a number
of insights into GRFT’s serum parameters. First, GRFT does not appear to be
extensively distributed in body water following intravenous administration.
Second, GRFT displays a multi-phasic half-life, with half-life increasing after a
very rapid elimination phase. GRFT concentrations 8 hours after either
subcutaneous or intravenous administration were comparable, suggesting that in
non-emergency settings, subcutaneous dosing may be a viable selfadministration method. Regardless, physiologically relevant concentrations
GRFT persisted for up to 96 hours in serum whether dosed intravenously or
subcutaneously.
Active GRFT is rapidly excreted by the kidneys, though proteolytic degradation
may be occurring.
Studies into the method of elimination displayed a strong excretion of
active GRFT concentrations immediately following intravenous dosing. However,
over a 24 hour period, this fraction of GRFT excreted only accounted for
approximately 1-2% of all GRFT dosed into the system. Based upon studies of
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others detailing GRFT’s generally strong proteolytic resistance, yet susceptibility
to specific proteases, it is hypothesized that rapid protein degradation of free
GRFT may be occurring.
GRFT is not orally bioavailable at a detectable extent.
Both single oral dosing and 10-day chronic oral dosing revealed GRFT is
not orally bioavailable to a detectable level. A single oral dose of GRFT, tracked
at 8 time points after oral administration failed to yield detectable concentrations
of GRFT in either serum or urine. Further, a 10-day chronic oral dosing study
was conducted, to account for the possibility of an accumulation effect. All
animals in that study, in which animals were orally administered by gavage with
GRFT at two concentrations, failed to display detectable GRFT concentrations in
serum at either day 5 or 3 hours after dosing on day 10. These results would
confirm that orally dosed GRFT is incapable of achieving potentially therapeutic
concentrations in serum.
GRFT is a potential orally dosed rectal microbicide.
Despite studies showing GRFT is not orally bioavailable in rats, active
GRFT concentrations were found in fecal material of rats orally dosed with
GRFT. These concentrations were dependent upon amount of GRFT orally
dosed. These GRFT concentrations, however, were only a very small fraction of
GRFT dosed. Nonetheless, fecal extracts prepared from fecal pellets displayed
strong neutralization activity in HIV-env pseudovirus neutralization assays.
Accordingly, it appears that a fraction of active GRFT can pass through the
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digestive system intact. Given the site of many HIV infections are in the rectal
mucosa, oral dosing of GRFT may be a method of delivering active, potentially
protective concentrations of the protein to the rectal mucosa.
GRFT is tolerable in sub chronic dosing.
Subcutaneous dosing of GRFT every 3 days was tolerable over a 51 day
period. No changes were observed in CBC values, body weights, or weight gain.
Further, pathologist review of organ slides did not reveal any treatment related
pathologies. There were alterations in kidney weights with pre-immunized
animals. Further, alterations in some serum chemistries and cytokine levels were
observed. However, varying form of immune response (pre or passive
immunization) did not affect GRFT concentrations in serum or HIV-env
pseudovirus neutralization activity. Accordingly, GRFT would appear to be
systemically tolerable for intermediate term usage as an antiviral prophylactic or
therapeutic.
GRFT treatment can induce changes in serum proteome with chronic dosing.
Calorimetric analysis of serum protein interactions displayed changes over
time associated with GRFT treatment. At day 10, visual inspection of serum
thermograms revealed fairly analogous mean thermograms for all treatment
groups. Furthermore, no changes were observed in any curve parameter other
than First moment temperature (Tfm). In that group, pre-and passively immunized
animals displayed a mean Tfm lower than PBS or GRFT treated groups.
However, by day 52, there were significant alterations in treatment group
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thermograms in comparison to PBS-treated controls. Many parameters analyzed
revealed differences among groups, including passively-immunized and GRFT
treated groups. However, it appeared that pre-immunization was able to blunt
alterations in parameters. Pre-immunized groups were not generally statistically
different in their curve parameters versus PBS-treated controls. This would
seem to indicate a protective effect of an immune response associated with
GRFT treatment.
GRFT binding, in and of itself, does not shift serum thermograms.
While significant shifts in rat serum thermogram parameters were
observed following chronic treatment with GRFT, those shifts do not appear to be
attributed to the direct binding activity of GRFT. Serum spiked with varying
concentrations of GRFT and allowed to react for approximately 1 hour did not
display alterations in serum thermograms. With spiking concentrations greatly
exceeding those concentrations observed in serum following system
administration, it was believed that any characteristic binding changes would be
observed by saturation with GRFT. Given the lack of thermogram alteration in
spiked samples, it would appear that alterations in serum thermograms following
chronic GRFT treatment can be attributed to an immune response or alteration of
concentrations of low molecular weight proteins which bind to the more abundant
serum proteins.
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GRFT is capable of specific binding to proteins which do not possess
oligomannose glycans
Given GRFT’s long serum persistence observed following single and
chronic dosing, DSC and AP studies were conducted to detail the potential
interaction of GRFT with a number of ligands. Fluorometry results confirmed
specific binding activity of GRFT to a number of saccharide ligands including
glucose, mannose, maltose, mannan, and N-acetylglucosamine. These
interactions have been observed in other previous studies. Further, affinity
purification of human serum proteins with both FLAG-GRFT and FLAG-GRFTlecfusion proteins revealed a number of potentially relevant biological interactions.
Among these, interactions with complement and apoplipoproteins were the most
numerous in FLAG-GRFT purified groups. These data would confirm specific
binding interactions beyond N-linked oligomannose binding activity. However,
the effects of these interactions will require additional study.
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Summary
In summary, GRFT has displayed persistent anti-viral activity in serum,
even in the presence of an immune response, following systemic administration.
Further, physiologically relevant concentrations can remain in serum days
following subcutaneous administration. While long-term dosing may induce
biochemical changes and may have an immunosuppressive effect that will
require additional study, it would appear that subchronic dosing of GRFT is
tolerable.

Additionally, while lacking oral bioavailability in rats, oral

administrations of GRFT may have utility. A small fraction of orally dosed GRFT
can pass into the rectal mucosa via fecal material. This transit of active GRFT
may eventually allow for the usage of GRFT as an orally dosed rectal
microbicide.
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RECOMMENDATIONS FOR FURTHER STUDY
While GRFT is still a strong candidate for anti-viral prophylaxis and
therapy, a number of questions have been raised by these studies. It is
recommended that further research be conducted to address these questions.
What is the primary mode of GRFT degradation?
The studies in this work have consistently shown that GRFT can persist in
serum for a long period of time. However, the vast majority of GRFT dosed
disappears within 24 hours of dosing. Mass Balance experiments revealed only
a small fraction of GRFT was excreted through the kidneys after an initial burst of
excretion. Thus, it would appear that GRFT is degraded in some other manner.
Therefore, radiolabeling experiments may be necessary to follow GRFT’s journey
through systemic circulation. The radiolabeling could also be useful in tracking
the extent of GRFT’s distribution as well as persistence in specific organ groups.
What impact does GRFT have upon the kidneys?
Sub-chronic dosing of GRFT did display changes in kidney size when an
immune response was induced. However, at the day 55 of the study,
pathological differences were not observable between kidneys. A long term
administration of GRFT in the presence of an immune response may be required
in order to clearly delineate alterations in kidney structure and function. It is also
recommended that blood nitrogen urea, creatinine clearance, and total
glomerular filtration rate be tracked over the course of treatment. These may
provide valuable insights into GRFT’s effect on the kidneys.
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Does GRFT cause immunosuppression or immunotoxicity?
Sub-chronic dosing of GRFT in rats was observed to lower some
inflammatory cytokine levels in comparison to adjuvant pre-immunized animals
and PBS-treated controls. Further, affinity purification of human serum revealed
complement factors were recovered by FLAG-GRFT and FLAG-GRFTlec-. This
suggests that GRFT administration may have some immunosuppressive or
immunotoxic effect that could impair an immune response to invading pathogens.
Accordingly, it is suggested that GRFT complement binding be confirmed by
binding ELISA as well as the nature of GRFT’s mode of action to rule out a
functional depletion of complement. Therefore, additional in vivo and in vitro
tests will need to be carried to out determine whether GRFT impairs humoral
response, cellular responses of T-cells, natural killer cells, macrophages, or
granulocytes. Further, testing of host resistance to infection (bacterial, viral, and
tumor) will be necessary, with a concomitant observation for illness.
Can concentrations of active GRFT found in fecal matter be increased?
Oral dosing studies discovered that active GRFT is excreted in fecal
matter. Given that HIV infection often entails exposure of fluids to rectal mucosa,
GRFT’s presence in fecal material passing through the rectum may enable its
usage as a rectal microbicide. It is possible that GRFT presence in fecal material
will be able to seed rectal mucosa with potentially protective concentrations of
GRFT. However, mass balance studies detailed only limited passage of active
GRFT. Accordingly studies into methods of increasing active concentrations of
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GRFT may further highlight GRFT’s potential as an orally dosed rectal
microbicide. These could include dosage of GRFT concurrent with antacids,
protease inhibitors, or in nanoparticle suspension or controlled release
encapsulation. Further, experiments with radiolabeled GRFT may be useful to
determine whether degraded GRFT is systemically absorbed.
Does GRFT treatment affect the gut microbiome?
While GRFT may be a promising orally dosed rectal microbicide, its
impact on the gut microbiome will need to be assessed. The gut microbiome can
be crucial in health, as well as immune system function and regulation [Citations
needed]. Agents which alter the endogenous balance can result in loss of
beneficial bacteria or a blooming of harmful bacteria. Given that some bacteria,
such as E. coli use mannose for adhesion [243, 244], it is possible that GRFT
presence could compete with endogenous flora for mannose or other adhesion
molecules. Accordingly, a tracking of the speed and nature of gut microbiome
changes over long term oral administration of GRFT will be necessary to
eliminate the potential that oral GRFT treatment could result in negative health
consequences.
Determine the nature of GRFT’s interaction with apolipoproteins and complement
GRFT’s binding to human serum proteins has been documented in this
study. Particularly relevant were binding interactions with complement and
apolipoproteins. In particular, the binding with complement could have
physiological relevance. Complement deficiencies have been associated with
150

autoimmune disease. Thus, a functional depletion of complement through
binding interactions with GRFT in a chronic administration model could
potentially exacerbate those disease associations. Accordingly, determining the
nature of those interactions will be necessary. Experiments entailing surface
plasmon resonance assays, isothermal titration calorimetry, and biotin tag affinity
switching using a photosensitive cross-linker may yield important information
regarding specific binding interactions with GRFT.
How does chronic administration of GRFT affect serum thermograms?
Spiking of rat serum with GRFT did not alter thermogram parameters.
However, chronic administration of GRFT resulted in significant changes in
comparison to PBS treated controls. However, the exact causative nature of
these changes are unknown. DSC can yield information as to characteristic
changes that occur, but is limited to describe the exact nature of the protein
interactions causing the change. Accordingly, quantitative studies will be
necessary into the abundance of lower molecular weight proteins present in
altered samples. It is recommended that these chronic dosing studies be
repeated solely for the purpose of comparing the alterations in lower molecular
weight proteins. Cytokine panels may yield rough concentration changes in
GRFT treated groups. Further, MS analysis may be useful in identifying changes
in serum components – however, Ig and Serum Albumin depletion may be
required before sample processing to remove signal masking by the more
abundant proteins.
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Whether GRFT can be utilized in long term therapy (>6 month)
Studies to date have yielded positive results in examining GRFT’s
potential as a systemic therapeutic for viruses possess N-linked, oligomannose
glycans. However, given the changes observed in a 55-day treatment regimen,
longer-term studies will be necessary to determine the true extent of changes
induced. Parameters such as kidney weight, blood urea nitrogen, spleen weight,
and anti-GRFT antibody activity should be monitored to determine whether
GRFT will be suitable for long-term usage.
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List of Abbreviations
ADA

Anti-Drug Antibodies

ALB

Albumin

ALKP

Alkaline Phosphatase

ALT

Alanine Aminotransferase

Amyl

Amylase

ANOVA

Analysis of Variance

AP

Affinity Purification

Asn

Asparagine

AUC

Area Under the Curve

Ba

Basophils

BanLec

Banana Lectin

BCA

Bovine Gamma Globulin

BGG

Bicinchoninic Acid

BSA

Bovine Serum Albumin

BUN

Blood Urea Nitrogen
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Ca

Calcium

CBA

Carbohydrate Binding Agent

CBC

Complete Blood Count

CCR5

Chemokine Receptor type 5

CD4

Cluster of differentiation 4

Chol

Cholesterol

Cmax

Maximum Concentration

CMV

Cytomegalovirus

ConA

Concanavalin A

Cpex

Maximum Curve Height

Cpex1

Maximum Peak - Range 1

Cpex2

Maximum Peak - Range 2

Crea

Creatinine

CV-N

Cyanovirin-N

CXCR4

Chemokine Receptor type 4

DC

Dendritic cell

DC-SIGN

Dendritic Cell Specific ICAM-3 Grabbing Non-integrin

DNA

Deoxyribonucleic acid

DSC

Differential Scanning Calorimetry

DSF

Differential Scanning Fluorimetry

EDTA

Ethylenediaminetetracetic Acid

ELISA

Enzyme Linked Immunosorbent Assay

ENV

Envelope
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Eo

Eosinophils

ER

Endoplasmic Reticulum

G-CSF

Granulocyte Colony Stimulating Factor

Glob

Globulin

GM-SCF

Granulocyte Macrophage Colony Stimulating Factor

gp120

Glycoprotein 120

gp41

Glycoprotein 41

GRFT

Griffithsin

GRO/KC

Growth Related Oncogene Keratinocyte Cytokine

HA

Hemagglutinin

HAART

Highly Active Anti-Retroviral Treatment

HCL

Hydrochloride

HCT

Hematocrit

HCV

Hepatitis C Virus

HGB

Hemoglobin

HIV

Human Immunodeficiency Virus

HPLC

High Performance Liquid Chromatography

HSV

Herpes Simplex Virus

ID50

Inhibitory Dilution

IFN

Interfereon

Ig

Immunoglobulin

IgG

Immunoglobulin G

IL

Interleukin
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IP

Interfereon Inducible Protein

IP-10

Interfereon Inducible Protein 10

JEV

Japanese Encephalitis Virus

kDa

Kilodaltons

KSHV

Karposi's Sarcoma Associated herpesvirus

Ly

Lymphocytes

MBL

Mannose Binding Lectin

MCHC

Mean Corpuscular Hematocrit Concentration

MCP

Monocyte Chemotactic protein

MCV

Mean Corpuscular Volume

MIP

Macrophage Inflammatory Protein

Mo

Monocytes

MPV

Mean Platelet Volume

MSM

Men who have sex with men

PBMC

Peripheral Blood Mononuclear cell

PBS

Phosphate Buffered Saline

PBS-T

Phosphate Buffered Saline - Tween 20

PEP

Post Exposure Prophylaxis

PHA

Phytohemagluttinin

Phos

Phosphorus

PLT

Platelet

PrEP

Pre-Exposure Prophylaxis

RBC

Red Blood Cells
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RDW

Red Blood Cell Width

RNA

Ribonucleic acid

SARS-Cov

Sudden Acute Respiratory Syndome CoronaVirus

Ser

Serine

SVN

Scytovirin

TasP

Treatment as Prevention

Tbil

Total Bilirubin

TBS

Tris Buffered Saline

Tfm

First Moment Temperature

Thr

Threonine

Tmax

Maximum Temperature

TMB

3,3'5,5'-tetramethylbenzidine

TMV

Tobacco Mosaic Virus

TP

Total Protein

Vd

Volume of Distribution

VEGF

Vascular Endothelial Growth Factor

WBC

White Blood Cells
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